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Malaria is an increasingly serious problem in sub-Saharan Africa. It exacts an 
enormous toll on the health of children, killing more than 1.5 million each year.
It also presents an obstacle to national development because of its high human and 
economic costs. Malaria in Africa is again the focus of concern and commitment 
by national governments and international organizations after a period o f neglect 
during the eradication program o f the 1950s and 1960s. The largest, most no­
table, and most successful example of this renewed interest was the malaria compo­
nent of Africa Child Survival Initiative-Combatting Childhood Communicable 
Diseases project (1982-1993), funded by the United States Agency for Interna­
tional Development to help African countries improve their children’s health. The 
progress o f the malaria component in policy and leadership development and in 
formulating effective interventions in the 12 malaria-endemic sub-Saharan African 
countries participating in the project provides the basis for the technical and pro­
grammatic recommendations outlined in this document, Addressing the Challenges 
o f  M alaria Control in A frica. The document is written especially for those involved 
in technical and programmatic aspects o f public health programs in sub-Saharan 
Africa.
The document defines the problem of malaria, its impact, biology, and epidemiol­
ogy; outlines interventions for malaria control; and describes requirements for an 
effective malaria control program.
Plasmodium  fa lc iparum , the parasite that is responsible for most o f the malaria 
infections and almost all malaria-associated death in Africa, affects children in one 
o f three ways: acute malaria illness, chronic or persistent malaria parasitemia with 
anemia, or perinatal malaria infection in the mother, which can cause low birth 
weight and early infant mortality. Groups at risk are identified, and interventions 
to manage and prevent these three classifications of disease are described in de­
tail—diagnosis, patient management, and criteria for selecting antimalarial drugs. 
The appropriate use o f chemoprophylaxis is discussed, and factors involved in 
embarking on a program using insecticide-impregnated bed nets are considered.
O f course, interventions can achieve their objectives only when implemented. 
Therefore, a malaria control program that can successfully conduct these activities 
is essential, and, in this document, the necessary components of a malaria control 
program are described. Ideally, the malaria control activities should be integrated 
with other disease control activities to capitalize on aspects o f their shared imple­
mentation. The challenge ahead is to implement effective malaria control pro­
grams based on locally appropriate, efficacious interventions that will improve child 
survival in Africa.
INTRODUCTION
I N T R O D U C T I O N
This document reviews the increasingly severe problem of malaria infection and 
disease in sub-Saharan Africa, describes interventions for managing and preventing 
the disease, and outlines requirements for a malaria control program. The docu­
ment is designed to assist those involved in developing and implementing public 
health programs in this region.
The perception o f malaria as a difficult disease that requires complex intervention 
strategies has been used to explain the failure o f the global eradication program of 
the 1950s and 1960s. Although complexity exists in biologic, epidemiologic, and 
programmatic features, by examining the components o f disease impact and formu­
lating interventions that address these components, policy makers can develop 
successful malaria control programs based on realistic objectives.
The basis for the technical and programmatic recommendations is the experience 
o f the malaria component of the Africa Child Survival Initiative-Combatting Child­
hood Communicable Diseases (ACSI-CCCD). Thirteen sub-Saharan African 
nations participated in this effort funded by the United States Agency for Interna­
tional Development. During the course o f the 12-year project, all 12 countries 
with endemic malaria made important progress in developing malaria policies and 
programs and in implementing interventions to improve child survival. The rec­
ommendations in this document are based on the most effective interventions 
devised as a result o f CCCD operational research and introduced in malaria control 
programs in CCCD countries.
In addition, the ACSI-CCCD work is the basis o f two other documents. Control­
ling M alaria in Africa: Progress and  Priorities  reviews project accomplishments and 
activities in participating countries and highlights priorities for malaria control for 
the next decade. M alaria prevention in pregnancy: the effects o f  treatm ent and p ro ­
phylaxis on p lacen ta l malaria infection, low birth weight, and fe ta l, infant, and  child  
survival presents the results o f a major study conducted in Mangochi, Malawi, from 
1987 to 1990. All three documents are available from the ACSI-CCCD Technical 
Coordinator, International Health Program Office, Centers for Disease Control 




M A L A R I A ’ S  I M P A C T
T h e  i m p a c t  o f  t h e  p r o b l e m
Eighty to ninety percent of the world's malaria occurs in sub-Saharan Africa; in this 
region, the health and economic burden o f malaria surpasses that o f all other dis­
eases. With an increase in areas under irrigation and the growth of more densely 
populated areas, development efforts in Africa have permitted the spread o f this dis­
ease. At the same time, by virtue of the direct costs of treatment and control pro­
grams and the indirect costs o f population morbidity and mortality, malaria is a major 
obstacle to development efforts (Bruce-Chwatt 1954; Shepherd 1991).
The process of malaria infection and disease begins when an infected mosquito trans­
mits the parasite to a person (Figure 1). Infection may lead to disease in one o f three 
pathways: acute febrile illness (classical malaria), chronic (or recurrent) infection 
resulting in anemia, or a perinatal effect, with the infected placenta in a pregnant 
woman leading to low birth weight (LBW). Each o f these can increase a child's risk 
o f dying, either as a direct result o f malaria disease or o f its complications, anemia and 
LBW (major risk factors for infant mortality).
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MALARIA DISEASE Acute Malaria: Each of the 125 million Afri­
can children less than 5 years of age living in 
malaria-endemic areas may experience from 5- 
10 acute febrile episodes that resemble malaria 
each year (Breman and Campbell 1988). 
Between 25% and 50% of these episodes will be 
due to malaria parasites. O f these infections, 
approximately 0.5%-1% are severe and life- 
threatening (Marsh 1992). For these cases of 
severe and complicated malaria, the in-hospital 
case fatality rate is between 15% and 20% 
(World Health Organization [W HO] 1990). 
Roughly 1.5 million children die every year of 
malaria in sub-Saharan Africa.
MALARIA DISEASE
M ALARIA DISEASE
Chronic Malaria: Red blood cells are 
destroyed during the course of a malaria infec­
tion, and bone marrow suppression during 
parasitemia limits the production of replace­
ment red blood cells, causing many patients to 
become anemic. The death toll for malaria- 
associated anemia has only recently begun to 
be appreciated; malarial anemia may be associ­
ated with 10-30% o f in-hospital pediatric 
deaths in sub-Saharan Africa (Lackritz et al. 
1992a) and may be an important contributing 
factor or cause of up to 75% o f malaria-associ­
ated pediatric deaths (Greenwood et al. 1987).
Perinatal Malaria: Twenty-two million Afri­
can women become pregnant each year in 
malaria-endemic areas and are at risk for 
malaria infection during their pregnancy. 
Malaria infection during pregnancy increases 
the chance of delivering a LBW baby (<2500 
grams). Infant mortality for babies born 
weighing less than 2500 grams is more than 4 
times that for normal birth weight babies 
(Kramer 1987). Malaria, which contributes to 
5%-10% o f LBW-associated infant deaths in 
sub-Saharan Africa, is one of the few factors 
associated with LBW and infant mortality that 
can be managed or prevented during preg­
nancy.
B I O L O G Y  A N D
E P I D E M I O L O G Y
T h e  B i o l o g y  a n d  E p i d e m i o l o g y  o f  M a l a r i a
The biology of the life cycle of the parasite is summarized in Box 1.1. The propor­
tion of persons affected by acute malaria (complicated or uncomplicated), chronic 
malaria (malarial anemia), or perinatal infections will vary from region to region, 
depending on the topography, altitude, temperature, humidity, rainfall, and the 
opportunity for human-vector contact. For these reasons, malaria control programs 
must be tailored to individual settings, and the particular manifestations of malaria 
infection in that setting must be taken into consideration.
Box 1.1 Life Cycle o f the Malaria Parasite in Humans
Four species of malaria parasite are capable of infecting humans. Only two species, Plasmodium 
falciparum and Plasmodium malariae, are important in Africa. P. falciparum is responsible for over 
90% of the malaria infections and essentially all malaria mortality in sub-Saharan Africa. Infections 
with P. malariae generally are not serious, but may be associated with nephrotic syndrome. Plas­
modium vivax is limited to North Africa, and Plasmodium ovale is responsible for <1% of infec­
tions; neither is associated with substantial morbidity and mortality.
Box Figure 1.1 Life Cycle o f the Parasite
S p o ro zo ites  in jected  into b lo o d stream  w h en  
fe m a le  m osquito  ta k e s  a  blood m ea l
In th e  m osquito  gut, g am eto cy tes  
d e ve lo p  in to  g a m e te s , zyg o tes , 
ookinetes , and  oocysts, resu lt­
ing in th e  production of in fective  
sporozo ites
G am e to c y te s  ing es ted  by fe m a le  
Anopheles  m osquito  w h e n  tak ing  a 
blood m eal
£x.Q-£.rylhr.Qcyti.s.. 
(hep atic ). C yc le) 
S p o ro zo ites  in fect liver ce lls  an d  
d eve lo p  into sch izonts , w hich  
re le a s e  m e ro zo ites  into th e  b lood­
s tream
\
E rythrocytic C vc le  
M e ro zo ite s  in fect red blood  
cells  to form  sch izonts  that  
re le a s e  m ore m e ro zo ites
S o m e  m e ro zo ite s  that in fect red  
blood ce lls  d e v e lo p  as  m a le  or 
fe m a le  g am eto cytes
Infected female Anopheles mosquitoes can transfer malaria parasites to humans while feeding 
on human blood. Sporozoites in the mosquito's saliva enter the blood and are carried immedi­
ately to the liver. They grow and divide in liver cells, each sporozoite giving rise to thousands of 
merozoites. These are released from the liver 1-2 weeks after the mosquito bite {P. falciparum) 
or 2-4 weeks following the bite (P. malariae). The merozoites invade red blood cells and mature 
first into trophozoites and then into schizonts over the next 48 (P. falciparum) or 72 hours (P. 
malariae). The infected red blood cells eventually rupture, releasing many merozoites which 
then invade new red blood cells and initiate new cycles of growth and replication. The symptoms 
of acute malaria (fever, chills, aches, and pains) are produced when the schizont-infected red cells 
burst. Sexual forms of the parasite (gametocytes) develop in red blood cells after 7-10 days, but 
their union occurs in the mosquito gut, following a blood meal in which both male and female 
gametocytes are ingested by the mosquito. Following maturation and multiplication, the sporo­
zoites migrate to the salivary glands of the mosquito and are available to be injected during a sub­
sequent blood meal.
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E P I D E M I O L O G Y
The epidemiology of malaria is determined by the efficiency of the mosquito vector 
(i.e., the capacity to transmit the malaria parasite), the intensity and the stability of 
malaria transmission, and human susceptibility and immune response.
In sub-Saharan Africa, the predominant species of anophelines, especially Anopheles 
gambiae, Anopheles arabiensis, and Anopheles funestus, are highly efficient vectors 
because their preferred sources for blood meals are humans. A. gambiae are especially 
efficient because they dwell and bite indoors at times when people are likely to be 
inside, and they support the 
development of the parasite well.
The intensity of malaria transmis­
sion in Africa far exceeds that o f 
other malaria-endemic areas in 
the world (Coluzzi 1992); this 
caused the international eradica­
tion effort to exclude the region 
from its program in the 1950s 
and 1960s. As mosquito control 
was the central strategy o f the 
eradication program, the inten­
sity o f transmission in Africa and 
the limited health infrastructure 
available to support the program 
were viewed as impediments to 
the inclusion o f sub-Saharan 
Africa (with the exception of 
Ethiopia, South Africa, and Zim­
babwe) in eradication efforts.
Malaria transmission is generally 
stable across most of sub-Saharan 
Africa (Box 1.2). Because of 
multiple opportunities for expo­
sure to the malaria parasite, 
adults (except for pregnant women) have developed immunity to malaria infection. 
Therefore, young children and pregnant women are the groups at highest risk for 
malaria disease. In areas where transmission is unstable (desert fringe areas, newly 
developed agricultural areas, areas where large population movements occur), resi­
dents will not have acquired adequate immunity to malaria infection or illness. In 
these settings, all age groups and persons are at risk, and the potential for malaria epi­
demics exists.
The risk of malaria infection is determined by exposure to infected mosquitoes. The 
risk o f malaria illness is determined by the individual's immunologic response to 
infection, which in turn depends on the frequency and duration o f previous malaria 
infections (Greenwood, Marsh, and Snow 1991). Therefore, in endemic areas, young
Box 1.2 Measuring Malaria Transmission
The standard measure of malaria transmission may 
be expressed as the entomologie inoculation rate 
(EIR), or the number of infective bites per person per 
time interval (e.g., year). The EIR is calculated by de­
termining the number of bites per person per night 
for a given species and then multiplying by the sporo- 
zoite rate (the proportion of Anopheles infected with 
malaria sporozoites). The result, die average number 
of infective bites per person per night, is multiplied by 
365, and the annual EIR is obtained.
Malaria transmission can be maintained when the 
human population receives about 0.33 infective bites 
per person per year (in other words, transmission will 
be maintained as long as, on average, each member of 
the population is infected once every 3 years) (Mac­
donald 1957). In The Gambia, transmission intensity 
is about 4 infective bites per person per year; in east­
ern Kenya, the annual rate is nearly 10 infective bites 
per person. Higher rates have been reported for 
Western Kenya (several hundred infective bites per 
person yearly) and northern Nigeria (about 100 in­
fective bites per person yearly). Intermediate rates 
have been reported recently from Malawi with trans­
mission intensities of 15-30 infective bites per person 
per year.
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children and any individuals moving from nonendemic areas are at high risk for 
malaria illness if they become infected. The most important manifestation o f malaria 
immunity is the capacity to suppress infection and to tolerate infection with few 
symptoms.
In areas o f intense P. falciparum transmission, newborns have an apparent protection 
from malaria infection and severe malaria illness for 2-6 months (Marsh 1992), coin­
ciding with the approximate duration of antibodies that pass across the placenta to 
the fetus. Once this transplacental protection wanes, young children are at risk for 
the full range of disease consequences of parasitemia. Children who survive repeated 
episodes of malaria gradually develop the capacity to contain infection at lower, non- 
lethal densities and to sustain parasitemia without becoming ill.
In settings o f high malaria transmission, women o f reproductive age have developed 
a high degree of immunity through repeated exposure to the parasite; however, dur­
ing pregnancy, and particularly during the first pregnancy, they experience increased 
susceptibility to malaria. This may be due, in part, to the presence o f the utero-pla- 
cental space, which apparently provides an immunologically safe place for parasite 
development and replication (McGregor 1984). The malaria infection, although not 
causing severe illness in the mother, contributes to low birth weight of the infant. In 
subsequent pregnancies, malaria infection (of both peripheral and placental blood) is 
less common, and malaria's contribution to low birth weight diminishes.
Several genetically determined traits afford protection against malaria. These include 
sickle cell trait (Miller 1992), which limits the development o f higher density infec­
tions and thus diminishes the risk o f severe malaria, and recently defined immune 
regulatory genes and their encoded human leukocyte antigens, which when present, 
decrease the risk of severe malaria (Hill et al. 1991).
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I N T R O D U C T I O N
I n t r o d u c t i o n
The three disease classifications-acute febrile illness, chronic infection, and perinatal 
infection-present distinct challenges to manage or prevent malaria illness. The avail­
able interventions of case management and prevention (Table 2.1) are discussed in 
this section.
Table 2.1 Interventions Linked to Disease Classification
Disease Classification
Acute malaria (complicated and 
uncomplicated)
Chronic malaria (anemia)
Perinatal malaria (placental in­
fection and LBW)
Case M anagement
Prompt diagnosis and timely use 
of an effective antimalarial drug 
with supportive care, patient ed­
ucation, and referral
Prompt diagnosis and treatment 
of each acute illness and manage­
ment o f its consequences (e.g., 
anemia), patient education, and 
referral
Prompt diagnosis and treatment 
of acute illness episodes and pre­
vention throughout pregnancy 
using intermittent therapy or 
chemoprophylaxis with an effec­
tive and safe antimalarial drug, 
patient education, and referral
Prevention
Chemoprophylaxis and personal 
protection
Chemoprophylaxis and personal 
protection
Chemoprophylaxis and personal 
protection
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MALARIA DISEASE
Introduction
Untreated malaria infections can rapidly progress to severe, life-threatening illnesses 
and death (W HO 1990). For this reason, prompt recognition and treatment of acute 
disease have become basic elements in malaria control efforts.
A person with a malaria infection may have acute symptoms, usually fever and mal­
aise; the disease may progress to include central nervous system signs (e.g., encepha­
lopathy), anemia due to red blood cell destruction, and other organ system 
involvement. O ther diseases may be associated with similar clinical symptoms, and 
the challenge of treating acute malaria involves deciding when to provide antimalarial 
treatment in circumstances where it may not be possible to make a specific diagnosis.
The choice o f a specific antimalarial drug depends on the species of parasite involved, 
the severity o f clinical illness, local parasite drug sensitivities, and the facilities avail­
able for administering treatment.
At-risk groups
In malaria-endemic areas, malaria should be considered in the differential diagnosis 
o f virtually any febrile illness in a young child. Children less than 5 years of age are at 
particular risk o f severe malaria-related morbidity and mortality; those between 6 and 
36 months are at highest risk for dying of malaria. Others at high risk for malaria 
infection are nonimmune travelers, workers (including the military) transferred from 
nonmalarious areas, and refugees. When malaria is introduced to an area, or re­
introduced as a result o f changes in ecology or weakened malaria control practices, 
the entire population may be at risk. These nonimmune persons can suffer malaria 
morbidity and mortality comparable to that o f the young sub-Saharan African child 
(Marsh 1992).
Recognizing acute malaria
Clinical diagnosis o f  acute malaria. Fever or history of fever is the usual clinical basis 
for the diagnosis o f malaria. Most patients, or their parents, will note fever as an early 
symptom. Because body temperature can rise and fall in conjunction with the parasite 
life cycle, patients with malaria may be afebrile (axillary temperature <37.5° C) at the 
time of presentation to a health care facility. Among such patients, a history o f recent 
(within 48 hours) fever may be the only basis for presumptive treatment o f malaria.
Under ideal conditions, patients in malaria-endemic areas presenting with fever and 
malaise would receive comprehensive evaluations including a detailed history and 
physical examination, blood films for malaria parasites, and additional laboratory 
investigations (hemoglobin, blood glucose, blood culture, complete blood count, 
chest radiograph, lumbar puncture) as indicated to exclude other possible diagnoses. 
Even with these diagnostic tests, however, diagnosing acute malaria may be difficult
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because the signs and symptoms (fever, headache, malaise, nausea and vomiting, 
cough, rapid respirations) are also seen in patients with other common infections, 
such as respiratory infections or diarrheal disease, and because malaria parasitemia 
may coexist with any o f these diseases.
The laboratory diagnosis o f malaria disease (in contrast to malaria infection) is ham­
pered by the fact that, in endemic areas, a substantial portion of asymptomatic indi­
viduals may have malaria parasites circulating in their blood, and people with fever 
from another cause may also have incidental parasitemia, thus compromising the 
diagnostic significance o f a positive blood film in febrile long-term residents of these 
areas. Thus, the presence of parasitemia should not preclude an aggressive search for 
other causes of fever.
The diagnosis of malaria based on fever or a history of fever is sensitive in identifying 
patients with parasitemia (Redd et al. 1992) (Box 2.1). This definition lacks specific­
ity, however, because it inevitably includes persons (parasitemic as well as apara- 
sitemic) with fever from some other cause. Seasonal or regional differences in 
malaria transmission patterns and seasonal fluctuations in other illnesses (meningitis, 
pneumonia, gastroenteritis) will alter the positive predictive value of this definition 
(Rougemont et al. 1991; Olivar et al. 1991). Efforts to improve the definition by 
including additional symptoms will increase specificity at the expense o f sensitivity.
Box 2.1 Sensitivity, Specificity, and Positive Predictive Value o f Malaria Diagnosis
The objective of the diagnostic process for malaria is to identify pauents who need treatment 
for malaria. Because microscopic diagnosis is generally unavailable in Africa, fever or a recent his­
tory of fever is the usual clinical basis for diagnosing malaria.
Fever or history of fever is a sensitive case definition. In other words, fever is likely to identify 
most children with malaria parasitemia. However, since most children who are ill have fever, the 
disadvantage of this case definition is that its specificity, its capacity to exclude aparasitemic chil­
dren, is low. If children are treated on the basis of this case definition, many of those receiving 
antimalarials will be aparasitemic.
The positive predictive value of fever as the case definition for malaria (the probability that a 
febrile child will be parasitemic) is not always high. When fever or history of fever was used as the 
clinical case definition for malaria in Zimbabwe, only 27% of children clinically diagnosed as hav­
ing malaria were also parasitemic. In a study in Malawi, 37% of children with fever (according to 
mothers' histories) and 47% of children with measured axillary temperatures >37.5° C had malaria 
parasitemia.
A case-control study in Niger showed a seasonal effect on the case definition: during the wet 
season, children with fever were more likely to be parasitemic than those who were afebrile. This 
association was not observed during the dry season. The positive predictive value of the defini­
tion varies with season in this setting.
Results of these studies show that epidemiologic characteristics such as season, in addition to 
clinical characteristics, are important in identifying those at risk for the complications of malaria. 
Available data are inadequate to translate these factors into specific recommendations for national 
programs. Malaria programs should begin to collect local epidemiologic information, such as sea­
son- and age-specific rates of parasitemia, as a first step in refining recommendations for treatment 
of children with malaria. Equating all febrile illnesses with malaria is a sensible starting point, but 
national programs recognize the limitations of such an approach. Additional studies are needed 
to identify which children are at risk for complications of parasitemia, including severe mortality 
and death. Treatment and prevention efforts should then be focused on these children.
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Laboratory diagnosis o f  acute malaria. The gold standard for the diagnosis of 
malaria infection remains the microscopic detection of parasitized red blood cells in 
properly stained peripheral blood films (Earle and Perez 1932). This method requires 
a microscope, slides, stains, and a trained microscopist. It is labor-intensive, taking 
5-30 minutes to examine the blood film of one child. In addition, it requires long­
term maintenance of equipment and skills o f the microscopist (W HO 1988).
Methods to simplify and accelerate the process are being developed.
• The Quantitative Buffy C oat1 method is commercially available (Becton Dickin­
son and Company, Franldin Park, New Jersey, USA) and is based on staining par­
asite DNA with a fluorescent dye. Parasites are detected after centrifuging blood 
collected in specially constructed hematocrit tubes (Rickman et al. 1989). This 
technique also requires long-term maintenance o f equipment and a skilled 
microscopist.
• Parasite DNA or RNA can be isolated from whole blood or from fingerprick 
blood collected onto filter paper, and various approaches to identify malaria para­
sites by molecular probes are being developed (Draper et al. 1986; Lai et al. 
1989).
• Some malaria parasite antigens can be recognized in enzymatic assays; diagnostic 
methods using ELISA or Dipstick are under investigation (Peyron et al. 1993).
Each o f these methods has its own constraints, and none has replaced microscopy; 
some may prove useful for large-scale screening or epidemiologic research.
Because the clinical syndromes of fever, encephalopathy, and anemia may be caused 
by other diseases, no single diagnostic test can distinguish among the various causes 
o f these conditions. If more information on fever (temperature, bacteriologic cul­
tures), parasitemia (presence or density), anemia (hemoglobin or hematocrit mea­
surement), and other possible sources o f infection (chest radiographs) can be 
acquired, the specificity of the diagnosis will improve. More microscopy and perhaps 
more hemoglobin or hematocrit measurements are needed; these tests are much less 
costly than chest radiographs or bacteriologic cultures and can provide essential 
information.
With these tools, patients could be diagnosed more accurately, thus allowing more 
judicious administration o f treatment. For instance, instead o f providing antimalari- 
als to all children with fever, those drugs could be provided only to febrile children 
who are parasitémie, and alternative diagnoses could be sought in aparasitemic febrile 
children.
Realistically, for the foreseeable future in Africa, more effective management o f pedi­
atric illness, including malaria, will come from the systematic application o f clinical 
criteria in the absence o f definitive laboratory confirmation.
1 Use o f  trade names is for identification only and does no t constitute endorsem ent by the Public H ealth Service or 
the U.S. D epartm ent o f  H ealth  and H um an Services.
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Definitions o f uncomplicated and complicated malaria
It is important to distinguish between patients with uncomplicated malaria illness 
and those with complicated disease because the management of the two differs mark­
edly. The former can be treated as outpatients, while the latter require more inten­
sive care.
Complicated malaria refers to patients with P. fa lciparum  parasitemia and any one or 
more of the following (WHO 1990):
• Altered consciousness
• Convulsions





Because these patients generally require parenteral medications (intravenous [IV] 
infusions or intramuscular [IM] injections), their treatment must be supervised by 
trained health workers.
Uncomplicated malaria refers to malaria disease in the absence of any signs of com­
plicated disease. In general, patients with uncomplicated malaria can be managed as 
outpatients, but parents or guardians should be alerted to the warning signs o f com­
plicated disease (above) and urged to return for further evaluation if the patient's 
clinical condition deteriorates.
Only a small proportion o f children infected with malaria parasites develop severe or 
complicated malaria (Greenwood et al. 1987), and it is difficult to predict which chil­
dren will develop life-threatening disease. For this reason, all young children with 
mild malaria should be treated as if they were at risk for developing more severe dis­
ease.
Managing acute malaria: objectives
• To prevent mortality associated with malaria infection.
• To prevent patients with uncomplicated malaria infections from developing life- 
threatening illness a n d /o r chronic malaria.
• To resolve the clinical symptoms and parasitemia associated with acute malaria 
infection rapidly and without sequelae.
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Managing acute malaria: strategy
• Promptly recognize acute malaria (complicated and uncomplicated); use effective 
antimalarial drugs at proper dosages in conjunction with supportive care, parental 
education, and referral when necessary.
Managing patients with uncomplicated malaria
Introduction. As management of uncomplicated malaria has to date had the objec­
tive of minimizing the risk of progression to complicated disease, treatment decisions 
must often be based on a malaria case definition (fever or history of fever) that is sen­
sitive, but not specific (Greenwood et al. 1991; Redd et al. 1992).
Choice o f  an antimalarial drug. The choice o f an antimalarial drug or drug regi­
men for an individual patient or for use in a control program should be based on the 
following criteria: efficacy, cost, availability, ease of administration, likelihood of 
compliance, and tolerance o f side effects.
Box 2.2 The Chloroquine Story
The first antimalarial drug, quinine, was discovered in the 16th century. Quinine, a natural 
product derived from the bark of the cinchona tree, was the mainstay of treatment until world 
supplies were truncated during World War I . Effective drugs were needed to treat troops in ma­
laria-endemic areas, and the first generation of synthetic drugs (pamaquine, mepacrine) emerged 
from a concerted research effort.
Chloroquine (CQ), a synthetic 4-aminoquinoline, was developed during World War II, one 
result o f an intense search for safer, more affordable, more efficacious malaria chemotherapy. 
These qualities, combined with its ease of administration, made CQ the most widely used anti­
malarial in the world.
Box Figure 2.2 The Spread o f Chloroquine-resistant P. falciparum Malaria in Africa
1978  1986  1993
Parasite resistance to CQ was first recognized in South America in 1961, in Southeast Asia in 
1962, and in Africa in 1978. Except for the Middle East, North Africa, Central America west of 
the Panama Canal, Haiti, the Dominican Republic, northern Argentina, and Paraguay, CQ-resis- 
tant parasites have been identified in all other malaria-endemic areas. Acceptable alternatives to 
CQ are few, and the inexorable spread of CQ resistance has been a major challenge for malaria 
control programs in endemic areas.
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Efficacy Increasingly, it is understood that the efficacy of an antimalarial used to 
treat children less than 5 years o f age (those at highest risk for severe illness and death 
due to malaria) can be judged by its ability to alleviate symptoms o f the disease, clear 
parasites, and allow an adequate parasite-free interval for hematologic recovery 
(defined as the return to pre-illness level o f hemoglobin concentration) (Bloland et 
al. 1993). As chloroquine (CQ) resistance has intensified, CQ 's subsequent failure 
to clear peripheral parasitemia results in shortened duration of clinical improvement 
and inadequate recovery from the associated anemia (Box 2.2). It is time to change 
to a drug that will clear parasitemia when resistance to treatment exceeds the follow­
ing dimensions: the mean sustained clinical recovery is less than 14 days and the 
mean hemoglobin concentration increase among children with anemia (<8 g /d L  ini­
tially) fails to increase by 1 g /d L  within 14-21 days. Experience suggests that these 
events occur in proportion to the frequency of high level resistance, mainly of the 
RIII type; the problem is o f epidemiologic importance when RIII resistance exceeds 
5%-10% (Box 2.3). In older individuals (those no longer at great risk for malaria 
mortality), the requirement for parasite clearance may be less critical.
Cost Several antimalarials are similar in terms of efficacy and safety. Consequently, 
price is an important determinant in selecting which agent(s) to include in a control 
program. Cost per treatment course should be compared for various choices; a rela­
tively high per tablet cost may be offset by a lower number of tablets required per 
treatment (Table 2.2) (Foster 1991). The cost per case effectively treated should be 
examined: a more expensive drug may ultimately cost less than a cheaper drug 
which, because of its reduced efficacy, must be administered more frequently. Costs 
could be further reduced by targeting the use o f the most effective antimalarials to 
those persons at greatest risk for malaria-associated mortality and severe disease.
Table 2.2 Drugs Available for the Treatment o f  Malaria
Drug
Route o f  
Administration Oral Regimen1
Cost per Adult 
Treatment2 (US$)
Chloroquine PO3, IM4, IV5 3 doses, over 3 days 0.08
Pyrimethamine/sulfa-
doxine
PO, IM Single dose 0.13
Quinine or quinidine PO, IM, IV 3 times daily for 3-7 
days
0.99-1.51
Tetracycline PO 4 times daily for 7 days 0.25
Mefloquine PO Single dose 1.92
Halofantrine PO 3 doses in 24 hrs 5.31
1 Oral regim en cited only
2 Cost o f drug only, excluding delivery 
3 PO = Oral
4 IM = Intram uscular 
5 IV = Intravenous
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Box 2.3 Drug Resistance
Resistance to most other antimalarial drugs (mefloquine, quinine, sulfadoxine-pyrimethamine) 
has developed, and is especially severe in Southeast Asia. Multidrug resistant parasites will even­
tually spread to Africa, but have not yet been detected in significant numbers.
Recognizing drug resistance
Drug resistance in malaria parasites is generally first noted by clinicians when patients fail to 
respond to the standard treatment regimen. For chloroquine, deterioration in drug efficacy is a 
gradual process; initially, only a few patients are affected. They may improve symptomatically, 
but parasitemia reappears within 3-4 weeks (RI, see chart below). In time, a substantial propor­
tion of the patient population will be infected with chloroquine-resistant P. falciparum, and the 
resistance may be such that parasitemia does not diminish at all after treatment (RIII) (See Box 
Figure 2.3).
Measuring drug resistance
The development of drug resistance in a population of malaria parasites can be measured in 
vivo (by noting inadequate responses to properly administered treatment) or in vitro (by measur­
ing the effect o f various concentrations of the drug on the growth of malaria parasites in culture). 
For operational purposes, in vivo testing is most useful. Recent data on the long-term effects of 
persistent parasitemia (Bloland et al. 1993) support the use of an expanded 28-day in vivo test of 
drug efficacy to include clinical and hematologic follow-up evaluation of study subjects when the 
7-day in vivo test demonstrates moderate to high levels of RII and RIII resistance.
Box Figure 2.3 Resistance Levels
I S en s itiv ity  (S )VuA
\
R I R e s is ta n c e , d e la y e d  re c ru d e s c e n c e
I l \ l  l..I, L ----------------------- ^  1
\  /
R I R e s is ta n c e , e a rly  re c ru d e s c e n c e
„  : r-
V R II R e s is ta n c e
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R III  R e s is ta n c e
. . ! ; _ : _ L i ...i - ...... -
0  1 2  3  4  5  6 7  14  21 2 8
___________1 | D a y s  after s ta rt o f tre a tm e n t on  D a y  0
'STANDARD TEST ' 7-day obseivation
Reproduced by permission o f  W H O , Geneva, from:
Technical Report Series N o. 529, Chem otherapy o f  M a­
laria and Resistance to  Antimalarials. 1973.
Staying ahead o f drug resistance
The malaria parasites have the capacity to develop resistance to a wide range of drugs, and 
widespread use of any drug will contribute to the development of resistant parasites. Therefore, 
it is essential to continue to monitor antimalarial drug resistance and to develop new antimalarial 
drugs.
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Availability Once drugs are chosen for a control program, a steady drug supply must 
be maintained, and the drug must be available at all places where malaria drugs are 
dispensed, e.g., hospitals, dispensaries, shops. A program predicated on the prompt 
and effective treatment o f febrile illness will be undermined if the recommended 
drugs are not readily available.
Compliance and ease o f administration As noted in Table 2.2, many of the drug regi­
mens require repeated dosing, and their efficacy requires the patient to take the drug 
repeatedly. Poor compliance with the regimen will be the major determinant of poor 
effectiveness. As a consequence, single-dose regimens are much more likely to be 
effective in both an individual and a programmatic setting.
Side effects Side effects need to be considered when choosing an antimalarial regi­
men for a malaria control program. Common, but not severe, side effects may 
reduce compliance. For example, pruritus due to CQ  has limited its role in some 
populations. The possibility o f severe side effects from an antimalarial, even if rare, 
must be carefully weighed against its benefits.
In conclusion, the goal o f treating young children at high risk is to clear both symp­
toms and parasitemia. In the rare settings where CQ remains efficacious, it should be 
the first-line treatment. However, the best alternatives in many settings o f sub- 
Saharan Africa now are the combinations o f sulfa drugs with dihydrofolate reductase 
inhibitors (e.g., sulfonamide + pyrimethamine). These drugs are still efficacious and 
have the advantage o f being administered as a single oral dose. A single dose o f sulf- 
adoxine-pyrimethamine (SP) is only slightly more costly than CQ. Where the resis­
tance to CQ  surpasses 15% to 30% o f RIII level, the cost per case effectively treated is 
actually lower because o f the greater efficacy o f SP (Sudre et al. 1992). Although 
malaria parasites will inevitably become resistant to SP, targeting its use to high-risk 
groups (children less than 5 years of age, nonimmunes, pregnant women) may slow 
the development of drug resistance. Meanwhile, research into new antimalarial 
agents must continue in the attempt to keep ahead o f developing drug resistance.
Drug administration. Prompt treatment o f febrile illness Cerebral malaria can 
develop within hours. In most cases, however, there is an antecedent history of fever. 
Therefore, effective treatment should be provided at the earliest possible opportunity 
(Box 2.4). Treatment for acute uncomplicated malaria should be readily and reliably 
available in hospitals, health centers, clinics, pharmacies, dispensaries, and if impor­
tant parts o f the population lack access to formal health care facilities, in shops and 
homes.
Supervised administration When possible, the first dose of an oral antimalarial agent 
should be given under supervision. The patient should be observed for 30 minutes; 
if the child vomits during that time, treatment options include repeating the initial 
treatment (again, under supervision and with observation) or switching to a 
parenteral drug.
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Use o f antipyretics Children who 
have a body temperature above 
38° C and who are irritable or 
appear uncomfortable should 
receive an antipyretic. Paraceta­
mol, both safe and inexpensive, is 
the preferred antipyretic for chil­
dren. Mothers should under­
stand that even though the 
antipyretic will relieve the fever 
temporarily, it will not cure the 
cause of malarial fever, and so the 
antimalarial drug is essential.
Follow-up management Patients 
or their guardians should be 
instructed to return immediately 
if the patient's clinical condition 
begins to deteriorate (e.g., 
clouded consciousness, convul­
sions, or inability to eat or drink) 
or if the patient does not show 
significant clinical improvement 
within 72 hours o f starting treat­
ment.
Health care personnel should be trained to respond to patients who fail to improve 
after receiving any antimalarial treatment. It is important to distinguish between 
drug failure (represented by persistent parasitemia) and an inaccurate initial diagnosis 
in patients who remain symptomatic despite having received antimalarials. In fact, in 
most in vivo trials, very few children have both persistent parasitemia and fever unless 
RIII-resistant parasites exist. To make this distinction in patients with persistent or 
recrudescent fever, health care personnel should perform a thorough physical re­
examination and a microscopic search for peripheral blood parasites. Subsequent 
treatment should be based upon these clinical and laboratory findings.
Managing patients with complicated malaria
Introduction. In sub-Saharan Africa, the vast majority o f severe and complicated 
malaria occurs in children less than 5 years of age who are infected with P. falciparum. 
Nonimmune individuals are also at risk o f developing life-threatening falciparum 
malaria, but they represent a small fraction o f patients in sub-Saharan Africa with life- 
threatening malaria.
The clinical spectrum of severe malaria in children is different from that in adults. 
Adults with severe falciparum infections may develop multiorgan system failure 
(adult respiratory distress syndrome, hemorrhagic diatheses, and hepatic and renal 
failure). Among children, complicated malaria is manifested as two clinical syn­
dromes: cerebral malaria and severe anemia.
Box 2.4 H ow Prompt Should 
"Prompt" Treatment Be?
Uncomplicated malaria can become complicated 
very quickly. It is not uncommon for mothers to ap­
pear at a health clinic carrying an unconscious child 
and to relate the following history: "She's had a fever 
for a day. We gave her chloroquine tablets and she 
played well all morning. Then she had a fit and she 
hasn't woken up since. " O f 131 comatose patients in 
Malawi, the mean duration of fever prior to admis­
sion was 47 hours, and the mean duration of coma 
before admission was only 8 hours.
Is it possible to intervene in such a rapidly progres­
sive illness? A small proportion of those infected with 
malaria develop complicated disease and the determi­
nants of this evolution are not known. Until the risk 
factors for severe disease are better defined, "prompt 
treatment" with an effective drug for all in whom ma­
laria is a likely diagnosis is the best approach. Since 
little is known about the natural history of malaria in­
fections, the safest assumption is that "prompt" 
means "now." This implies that antimalarial drugs 
should be available to people where they live, i.e., 
homes, shops, and local dispensaries, as well as in clin­
ics and hospitals and that people must know how to 
use them.
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Cerebral malaria may evolve over the course of 24-36 hours, beginning with such 
nonspecific signs and symptoms as fever, malaise, and headache. Very often, how­
ever, children begin convulsing or lapse into coma without any discernible warning 
(Box 2.4). The deceptive calm of the earlier stages of the infection and the rapidity 
with which symptoms can develop require that interventions be delivered promptly 
(Molyneux et al. 1989).
Life-threatening anemia can develop rapidly in patients with heavy parasitemia, or it 
may develop more slowly, over the course o f several incompletely treated or clinically 
undetected infections. The clinical picture is the same, regardless o f the speed with 
which it evolves: patients are pale, breathless, easily fatigued, and often slightly con­
fused (Lackritz et al. 1992a). Once cardiorespiratory compromise is evident, blood 
transfusion is required. For a more complete discussion o f anemia, see pages 24-28.
Differential diagnosis o f  complicated malaria. Altered consciousness is the hall­
mark of cerebral malaria, although its clinical presentation can also include convul­
sions, frank coma, confusion, abnormal respiratory rate or rhythm, hypertonicity, and 
posturing (W HO 1990). As in uncomplicated malaria, the differential diagnosis of 
altered consciousness in an African child includes a variety of illnesses (Box 2.5). In 
patients with a clinical picture consistent with cerebral malaria, antimalarial treatment 
should be administered while sequential blood samples taken at 8-12 hour intervals 
are examined for malaria parasites. Parasitemia may be found in patients uncon­
scious for reasons other than malaria. Therefore, the clinical decision to treat a given 
patient for cerebral malaria must include consideration o f the local epidemiology of 
severe malaria and an aggressive search for other etiologies (e.g., meningitis). When 
there is doubt, treatment should be started promptly and continued until the diagno­
sis is clarified.
Quantifying altered consciousness. Describing altered consciousness in an opera­
tionally useful way has been made easier by the development and validation of a coma 
scale. The Blantyre (Malawi) Coma Score (Molyneux et al. 1989) is helpful both in 
recognizing and following pediatric patients with severe malaria (Table 2.3). It is 
easily taught and learned, can be easily performed at the bedside, requires no special 
equipment, and has very little interobserver variability.
Table 2.3 Blantyre Coma Score
Best Motor Response* Best Verbal Response* Eye Movements
Localization 2 Normal cry 2
Withdrawal 1 Abnormal cry 1 Follows** 1
None 0 None 0 Does not follow 0
* Response to a painful stim ulus (sternal rub, pressure on supraorbital ridge, or nailbed). 
** Follows a bright object, m other, or exam iner's face.
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Box 2.5 Differential Diagnosis o f  Altered Consciousness
Care should be taken to exclude other causes of altered consciousness in children: meningitis, 
hypoglycemia, bacteremia, severe anemia. Each requires specific therapy and may be fatal if 
untreated.
The confirmatory diagnosis of meningitis is made when bacteria are identified in and cultured 
from the cerebrospinal fluid (CSF). The culture usually requires several days; antibiotic treatment 
is usually started on the basis of a cloudy appearance or gram stain of the CSF when the lumbar 
puncture is performed. Infected CSF is characteristically "cloudy" because of the increased num­
ber of white blood cells present.
Hypoglycemia (low blood sugar) can be caused by malaria, quinine treatment, any severe in­
fection (sepsis), gastroenteritis, and starvation. Hypoglycemic individuals can become confused, 
lose consciousness, or have convulsions. There are no reliable clinical clues for hypoglycemia, but 
blood glucose levels can be estimated easily at the bedside using a glucosometer. This allows the 
treatment (50% dextrose, intravenous) to be given immediately.
Blood cultures are required to make the diagnosis of bacteremia. Sophisticated laboratory fa­
cilities (sterile culture systems, incubator) are required, so firm diagnoses may not be possible in 
certain settings. However, a recent study from western Kenya suggests that up to 25% of pediatric 
hospital deaths were associated with bacteremia (Lackritz et al. 1992b).
Cerebral oxygenation can be impaired in patients with severe anemia (<5 g /d L  or 15% hema­
tocrit), especially when the basal metabolic rate is increased as it is in patients with fever. Clinical 
examination and a hemoglobin or hematocrit measurement can confirm this diagnosis.
If  a child is able to localize a painful stimulus (score 2), cries normally in response to 
painful stimuli (score 2), and can visually track an object (score 1), the child scores 
" 5" and does not have significant cerebral impairment.
For research purposes, children with P. falciparum parasitemia and coma scores o f 2 
or less in the absence of other causes of altered consciousness are considered to have 
cerebral malaria. They require parenteral medication and careful clinical attention.
Any altered consciousness is cause for concern (regardless of parasitemia); in malaria- 
endemic areas, sick children who meet the local epidemiologic profile and who are 
unable to take medicines by m outh should be treated as if they have cerebral malaria.
Specific antimalarial treatment. Children with cerebral malaria are unable to swal­
low and require parenteral treatment. CQ  resistance is now widespread among P. fa l­
ciparum parasites (Box 2.2) and for this reason, patients with severe malaria, 
particularly with altered consciousness, should be treated with quinine dihydrochlo­
ride or its stereoisomer, quinidine gluconate, by slow IV drip. When possible, the 
drug should be administered intravenously; pharmacokinetic studies indicate that 
therapeutic concentrations and steady-state levels o f drug are present shortly after the 
administration of a loading dose by slow IV infusion (Winstanley et al. 1992; Mansor 
et al. 1990). At least 3-4 doses of drug during at least 24 hours are required to attain 
a similar state in the absence of a loading dose. Rapid infusions o f quinine stimulate 
pancreatic release o f insulin and can precipitate hypoglycemia (Taylor et al. 1988). 
This complication can be avoided if the quinine is administered slowly (during 2-4
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hours) and a continuous source of glucose is provided (5% dextrose, 80 m l/kg  dur­
ing 24 hours through IV or nasogastric routes). Parenteral treatment with quinine 
should be continued until the patient is alert enough to eat and drink at which point 
treatment can be continued with either quinine tablets (for 7 days) or with a single 
treatment dose o f SP.
In health-care settings that lack the capacity to establish and maintain IV infusions, 
quinine can be administered as an IM injection (Mansor et al. 1990; Schapira et al. 
1993). Patients with Blantyre Coma Scores o f 3-4 can be treated with IM quinine 
entirely at peripheral health care facilities. Those with Coma Scores <2 should be 
referred to a center in which IV infusions and more intensive medical and nursing 
care are available. When a cerebral malaria patient is transferred from a remote site 
for more sophisticated care, treatment can be accelerated by giving the initial dose(s) 
of quinine via the IM route before or during the transfer. The loading dose o f qui­
nine (20 m g/kg) should be split into two 10 m g/kg  doses given 4 hours apart to 
minimize the risk of precipitating hypoglycemia.
Supportive care. Cerebral malaria patients also require good supportive care to 
minimize the complications associated with coma. Patients should be nursed lying on 
their sides to decrease the chances o f aspirating after vomiting. Regular assessments 
of the coma score are helpful; the most common causes o f a decrease in coma score 
after the start o f treatment are an unwitnessed convulsion, hypoglycemia, or the 
rapid development o f life-threatening anemia. Each of these requires a specific thera­
peutic intervention (anticonvulsants, 50% dextrose, packed red blood cell or whole 
blood transfusion). A steady supply o f fluids and glucose is essential; however, over­
hydration should not occur. These fluids can be administered by IV infusions or 
through nasogastric tubes, and they should be continued until patients are able to eat 
and drink.
Acute malaria: the future
Even with the best available care, the in-hospital mortality rate for severe and compli­
cated malaria in African children is about 20% (White et al. 1987; Molyneux et al.
1989). Quinine-resistant P. falciparum exists in Southeast Asia and is likely to spread 
to Africa. Efforts to develop and evaluate new drugs (e.g., halofantrine, artemisinine 
compounds) and to pursue novel approaches to the treatment o f acute malaria (com­
plicated and uncomplicated) should continue. However, to reduce overall (as 
opposed to in-hospital) mortality, it is critical to identify those at risk o f developing 
severe disease and to take specific measures to prevent infection and illness. Efforts 
are under way to identify epidemiologic and host genetic factors that will predict 
which children are at risk for severe disease. Interventions designed to halt the pro­
gression to life-threatening disease can then be targeted to this group.
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R e c o g n i z i n g  a n d  M a n a g i n g  t h e  
C h r o n i c  E f f e c t s  o f  M a l a r i a :
A n e m i a
Introduction
Recurrent or chronic P. falciparum infections occur in areas where transmission is 
intense or resistance to commonly used drugs exists. The most common clinical pre­
sentation o f chronic malaria is anemia, a decrease in the number of red blood cells 
(RBCs) in circulation. The destruction o f parasitized blood cells is an inevitable con­
sequence of malaria infection; in addition, malaria infection may impede RBC pro­
duction by unknown mechanisms and may increase the destruction of unparasitized 
RBCs.
Blood transfusions are required to treat 
severe anemia. Largely for technical reasons 
(collecting, storing, and preparing blood for 
transfusion requires special equipment and 
expertise), patients requiring blood transfu­
sions must be hospitalized. The spread of 
the human immunodeficiency virus (HIV) in 
sub-Saharan Africa has endangered the 
blood supply (Box 2.6) at the same time that 
the spread o f CQ-resistant parasites, by 
increasing the number o f inadequately 
treated patients, has created a larger popula­
tion of anemic individuals. Against this 
backdrop, the issues o f diagnosis, manage­
ment, and prevention o f chronic anemia 
assume greater urgency and importance 
(Box 2.7).
At-risk groups
As in acute malaria, the local epidemiology o f malaria is a major determinant o f risk 
groups for chronic malaria; the other contributing factor is drug efficacy. Individuals 
are unlikely to develop chronic malaria if treatment of the acute disease eliminates 
parasites from the peripheral blood.
Box 2.6 Transfusion-associated HIV  
Infection
Studies in Zaire have shown that pe­
diatric blood transfusions, given pri­
marily for the treatment of malaria- 
associated anemia, account for an es­
timated 25% of pediatric HIV infec­
tions and for 40% of HIV infections 
among children older than 12 
months of age (St. Louis et al. 
1993).
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Box 2 .7  Developm ent o f  Anemia
In areas o f stable malaria transmission, younger children are more susceptible to developing 
anemia. Studies in western Kenya identified an age-specific population at risk for death from severe 
anemia. Among hospitalized patients, those less than 2 years o f age were at greatest risk for severe 
anemia, blood transfusion, and anemia-associated mortality. O f all hospitalized children with he­
moglobins <5 g /d L , 93% were under 2 years o f age (<24 months old) (Lackritz et al. 1992a).
Among all blood transfusions given in three university hospitals in Cote d'Ivoire and in one 
district hospital in Kenya, two-thirds were given to  children, and approximately 20% of all hospi­
talized children were given blood. Twenty-nine percent o f all children admitted to a Kenyan dis­
trict hospital had H b <5.0 g /d L ; they had a mortality rate o f 18% (compared with an 8% mortality 
rate among children with H b >5.0 g /d L ). Children less than 36 months o f age accounted for 
92% of all children with H b <5.0 g /d L , 92% o f ali transfusions, and 87% of all in-hospital deaths.
Findings were similar in the communities surrounding the above-mentioned hospital in west­
ern Kenya: children less than 36 months o f age had the highest prevalence o f anemia and severe 
anemia and were the only age group in which malaria parasitemia was associated with anemia. 
Older children (70%) and women (30%) were often parasitemic, but there was no association be­
tween malaria parasitemia and anemia in these older age groups.
Among this very young age group, malaria and nutritional deficiencies are the two most im­
portant causes o f anemia. O ther causes, e.g., hookworm infestation, are not im portant until chil­
dren are older. Sickle cell disease, when it occurs, may also cause anemia in children.
Definition o f  anemia
The normal range for hemoglobin concentration is between 11-15 g /d L  (Table 2.4) 
(WHO 1968).
Table 2 .4  W orld H ealth  O rganization D efinitions o f  Anemia
Age H em oglobin  (H b ) (g /d L )
Children 6 mos.-6 yrs. <11




Table 2.5 indicates widely accepted hemoglobin and hematocrit ranges for mild, 
moderate, and severe anemia.
Table 2 .5  H em oglob in  and H em atocrit Ranges for Anemia
Degree o f Anemia H em oglobin  (H b )(g /d L ) H em atocrit (H ct) (%)
Mild 8 - 11 25 - 34
Moderate 5 - 8 15 - 24
Severe <5 <15
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Recognizing anemia
Clinical diagnosis o f  anemia. Patients with mild or moderate anemia are usually 
asymptomatic, and most diagnoses at this stage are made incidentally in the process of 
investigating other complaints.
Severe anemia can be detected on physical 
examination: patients have pale tongues, 
conjunctivae, nailbeds, and palmar creases. 
Patients with life-threatening anemia man­
ifest signs and symptoms of cardiac failure. 
(Box 2.8).
The clinical syndrome of life-threatening 
anemia is not circumscribed by a fixed 
range of hemoglobin concentrations, but 
is determined by the hemoglobin concen­
tration, the rapidity of the fall in hemoglo­
bin, the patient's physical condition, and 
the patient's level o f activity (Box 2.9).
Laboratory diagnosis o f  anemia. The
laboratory determination of hemoglobin 
concentration can confirm and quantify 
the clinical impression o f anemia. H em o­
globin concentration can be determined 
by several different methods, and reason­
able estimates are possible even without 
electricity.
An alternative to hemoglobin concentra­
tion as a measure of anemia is the packed 
cell volume, or hematocrit. A small sample 
o f blood is centrifuged, and the proportion 
o f the total volume of red blood cells is 
determined (normal range 35%-45%). In 
general, the hematocrit (%) is approxi­
mately three times the hemoglobin concen­
tration (g /dL ); the two measurements are 
essentially interchangeable.
Inexpensive laboratory tests are urgently 
needed to detect anemia early and prevent 
the inappropriate use o f blood transfusion.
Box 2 .8  The Pathogenesis o f  Life- 
threatening Anemia
The function o f hemoglobin is to carry 
oxygen to body tissues. When the supply of 
hemoglobin is diminished, as it is in anemic 
patients, the cardiovascular system 
compensates by delivering more blood to 
the tissues. To do this, the heart beats more 
rapidly. The patient breathes faster, 
increasing cardiac output. Eventually, if the 
hemoglobin concentration falls low 
enough, quickly enough, the heart cannot 
supply enough blood, and the entire 
cardiovascular system begins to fail. The 
level o f hemoglobin concentration at which 
this occurs depends on tissue needs. These 
increase with exertion, for instance, and 
with fever. Therefore, patients who are 
asymptomatic at rest may develop the signs 
and symptoms o f "high-output" cardiac 
failure if they become infected, or if they try 
to increase their activities.
Box 2 .9  Physical Findings in Anemia
The degree o f anemia in an individual 
can be estimated by inspecting areas o f the 
body where blood circulates close to the 
surface: in nail beds, palmar crcases, and 
conjunctivae. These areas become notice­
ably pale when the hemoglobin concentra­
tion falls to 5-6 g /d L .
When anemia is severe enough to cause 
cardiac failure, the usual signs and symp­
toms o f this syndrome are evident: rapid 
heart rate, shortness o f breath, and en­
larged liver. Patients may often be drowsy 
and confused because o f insufficient flow of 
oxygenated blood to the brain.
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Managing chronic malaria: objective
• To prevent anemia-associated mortality.
Managing chronic malaria: strategies
• Recognize patients with m ild/m oderate 
malaria-associated anemia and provide 
effective antimalarial treatment.
• Recognize patients with life-threatening 
anemia and provide supportive care and 
transfusion with blood screened for HIV 
and hepatitis B and C.
Managing patients with chronic malaria: 
anemia
Mild and moderate anemia. Patients with 
mild or moderate anemia are often asymptom­
atic, and the anemia is usually only recognized 
incidentally. When the anemia is associated 
with malaria, a significant improvement in 
hematologic status ensues from effective antimalarial treatment. Life-threatening 
anemia is less likely to develop if patients with malaria-associated anemia are recog­
nized early and treated properly (Box 2.10).
Severe anemia. Treatment decisions for severe anemia are based on the clinical con­
dition of the patient. When the anemia is not life-threatening (see below), it can be 
managed conservatively with rest as necessary, antimalarial drugs, nutrition, and 
micronutrient supplementation (iron, folate). Anemic children with signs of cardiac 
failure are at high risk for dying.
Blood transfusion. Laboratory capacities to group and cross-match blood from 
both donor and recipient and to screen donor blood for anti-HIV antibodies are pre­
requisites for safe blood transfusion (Box 2.11).
Box 2 .11  Transfusion and Survival
Studies in Kenya compared survival o f severely anemic children who were transfused with that of 
children who, because o f shortages o f supplies and banked blood, were not transfused (Lackritz 
et al. 1992a). Transfusion improved survival, but only among children with hemoglobins below 
5.0 g /d L  who also had clinical evidence o f cardiorespiratory distress (grunting, intercostal retrac­
tions, or nasal flaring). Because o f reliance on family donors for blood, transfusions were often 
delayed. Severely anemic children died early in the course o f their hospitalization, and transfusions 
given 2 or more days after hospitalization were not associated with decreasing risk o f death. Had 
transfusions been limited to children with hemoglobin <5.0 g /d L  and evidence o f distress and 
administered within 2 days o f admission, the num ber o f transfusions would have been reduced by 
nearly half without increasing mortality.
Box 2 .1 0  H em atologic Recovery with  
Proper Treatment
Studies in Zaire, Kenya, and Côte d'Ivoire 
have identified malaria as an important risk 
factor for severe anemia in both community 
and hospital studies. With the geographic 
extension and intensification o f chloroquine 
(CQ) resistance, many areas have reported 
an increase in the proportion o f children 
presenting to clinics with malaria and ane­
mia. In Kenya and Malawi, children with 
malaria and anemia (H b < 8g/dL ) were ran­
domly assigned to treatment with either CQ 
or sulfadoxine/pyrimethamine (SP). Those 
who received SP demonstrated twice the lev­
el o f hematologic recovery than those re­
ceiving standard CQ therapy. Persistent 
parasitemia is a major contributor to anemia; 
effective treatment can significantly improve 
pediatric hematologic status in areas o f CQ 
resistance (Bloland et al. 1993).
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Children with life-threatening anemia should receive 10-15 m l/kg  packed red cells. 
If it is not possible to administer packed cells, then 20 m l/kg  whole blood should be 
given (W HO 1990).
Administering blood to patients in cardiac failure can be dangerous, because the 
extra fluid may overwhelm the cardiovascular system. Blood transfusions should be 
given slowly (6 hours). Diuretics will also help by removing excess fluids.
Other supportive measures are important to improve survival o f severely anemic chil­
dren. Patients receiving blood transfusions should be observed frequently so that 
complications can be recognized and treated promptly.
Postdischarge follow-up. Recent data from Kenya suggest that severely anemic 
patients who survive hospitalization (with or without blood transfusion) remain at 
greatly increased risk o f dying within 2 months of discharge (Lackritz et al. 1992b). 
Further research is required, but these data suggest that in-hospital care may have a 
limited effect on longer-term survival and that management o f severely anemic chil­
dren may require more assiduous outpatient followup.
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C o n t r o l l i n g  M a l a r i a  i n  P r e g n a n t  M ALARIA  D ISEA SE
W o m e n
Introduction
In most of sub-Saharan Africa, malaria infection and higher density parasitemia are 
more common in pregnant women than in nonpregnant women o f comparable age 
and from the same area (McGregor 1984). In areas with lower levels o f malaria trans­
mission, women have limited exposure to the parasite and lower levels of acquired 
immunity. In these areas, malaria infection causes maternal illness and fetal loss 
through abortion or stillbirth more often than LBW. However, because malaria 
transmission in most o f sub-Saharan Africa is high, the main effect o f malaria in preg­
nancy is LBW.
Low birth weight is the most important risk factor for neonatal and early infant mor­
tality (Box 2.12). Malaria is one o f several causes o f LBW in populations of sub- 
Saharan Africa. Numerous maternal characteristics including short stature, low pre­
pregnancy weight, low weight gain 
during pregnancy, and severe ane­
mia are also associated with LBW.
A malaria-specific intervention 
should be able to reduce the inci­
dence of LBW, but the reduction 
will be proportional to the LBW 
attributable to malaria.
Proper planning for a malaria con­
trol program for pregnant women 
requires certain country- or region- 
specific information: the prevalence 
of malaria in pregnant women by 
parity, the incidence of LBW by 
birth order, the incidence or preva­
lence o f other adverse effects of 
malaria in pregnant women (e.g., 
febrile illness, anemia), and the effi­
cacy o f antimalarial drugs for use in 
pregnancy.
At-risk groups
Women in their first malaria-exposed pregnancy are at highest risk for the adverse 
effects of malaria (Box 2.13). In areas o f high endemicity where women are exposed
Box 2 .1 2  Low  Birth W eight
Low birth weight (LBW) is defined as birth 
weight o f <2500 grams. LBW is the primary risk 
factor for neonatal and early infant mortality in both 
developed and developing countries. In developing 
countries, neonatal mortality rates (NMRs) in babies 
with birth weights o f 2000-2499 grams and births 
weights o f <2000 grams are approximately 2 and 11 
times greater, respectively, than the NM R in normal 
birth weight babies.
Prematurity (gestation <37 weeks) and intrauter­
ine growth retardation (IU G R [low weight for ges­
tational age]) are the two contributors to  LBW. 
Compared with NMRs in normal birth weight ba­
bies, NMRs in IU G R babies and premature babies 
are approximately 2 and 10 times greater, respective­
ly-
Malaria has been recently shown to contribute to 
both IU G R and prematurity (Steketee et al. 1993).
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frequently to infective mosquito bites, most 
first malaria-exposed pregnancies are among 
primigrávidas. After exposure to malaria 
during pregnancy, women appear to 
develop a pregnancy-specific immune 
response, which is remembered in subse­
quent pregnancies. Consequently, a woman 
in her second pregnancy has acquired some 
ability to control malaria infection, and she 
is less likely to develop high placental and 
peripheral parasitemia and thus to suffer 
their effects (anemia and LBW). By the 
time a woman has had several malaria- 
exposed pregnancies, she will have devel­
oped a relatively high degree of pregnancy- 
specific immunity and may be considered 
protected.
Malaria infection in primigrávidas results in 
high parasite densities and is associated with 
LBW; malaria infections in subsequent 
pregnancies are of lower parasite density and 
contribute less to LBW (Steketee et al.
1987; Steketee et al. 1988). In addition,
LBW is most common in firstborn babies, 
regardless o f other factors such as malaria.
Consequently, primigrávidas and secundi- 
gravidas should be considered the groups at 
highest risk for adverse malaria-associated 
perinatal outcomes.
In settings where malaria transmission is 
highly seasonal, pregnant women are partic­
ularly at risk during and shortly after the 
high transmission season. In these locations, the interventions may be most effectively 
targeted to pregnant women only during these seasons.
Managing malaria in pregnant women: objectives
• To reduce malaria-associated LBW.
• To reduce maternal and fetal morbidity and mortality associated with malaria infec­
tion.
Managing malaria in pregnant women: strategies
Specific strategies are determined by the baseline data that define the malaria epidemi­
ologic setting and by the level of prenatal care available in the community. On the 
basis o f these considerations, three strategies emerge:
Box 2 .13  Malaria D uring Pregnancy
From work in The Gambia, McGregor 
(1984) has described malaria in pregnant 
women in the following way: Women of 
child-bearing age have developed a high 
degree o f immunity to the malaria parasite 
through repeated exposure and are not 
generally susceptible to the effects o f severe 
clinical malaria. However, pregnancy es­
tablishes within this immune host a highly 
vascular organ (placenta) that shields the 
parasite from destruction by extrauterine 
immune effector mechanisms and permits 
localized parasite replication. This shelter 
appears temporary and the presence o f the 
parasite in uterine and placental vasculature 
induces local responses that effectively re­
strict parasite replication. These local re­
sponses are least effective in the 'naive' 
uterine-placental interface o f primigrávidas, 
but increase in subsequent malaria-exposed 
pregnancies.
Although the immunologic mechanisms 
necessary to establish and maintain the lo­
cal response have not been further delineat­
ed, women in the first malaria-exposed 
pregnancy are at greatest risk and need tar­
geted control programs.
Following delivery o f the baby and pla­
centa (the repository o f parasites), the pe­
ripheral parasitemia in these women is 
rapidly cleared without further treatment 
with antimalarials (Nguyen-Dinh et al. 
1988).
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• Treat acute episodes of malaria.
• Prevent asymptomatic malaria infec­
tion with regular treatment or with 
chemoprophylaxis using either thera­
peutic or suppressive doses of an 
antimalarial drug.
• Prevent infection by reducing the 
risk of infective mosquito bites.
Managing pregnant women with  
malaria
Early recognition and treatment o f  
malarial illness. Febrile illness in preg­
nant women should be treated with an 
antimalarial drug. The choice o f antima­
larial drug depends on efficacy, safety, 
availability, and affordability (Box 
2.14). Chloroquine is the first choice in 
areas where it remains highly effective, 
but such settings are increasingly uncom­
mon. In African settings with CQ-resis- 
tant parasites, SP combinations or 
quinine are effective alternatives.
Because o f the high risk associated with 
malaria illness in pregnant women, other 
antimalarials (mefloquine, halofantrine) 
could be used, even though less informa­
tion on their safety is available.
Preventing malaria infection. Across 
sub-Saharan Africa, most pregnant 
women with peripheral parasitemia and 
placental malaria infection will be asymp­
tomatic. There are no clinical indica­
tions o f infection to alert the woman or 
health worker to proceed with treat­
ment. Consequently, a management 
strategy cannot be based solely on fever 
recognition and treatment. Antimalarial 
drugs need to be administered on a reg­
ular schedule during pregnancy; they will 
have both therapeutic (for women who 
are parasitemic at the time o f treatment) 
and prophylactic effects.
Selecting antimalarial drugs for pre­
vention during pregnancy. Only a lim­
ited number of effective antimalarial
Box 2 .1 4  D rug U se D uring Pregnancy
Selecting an antimalarial drug for use during 
pregnancy requires knowledge o f efficacy, avail­
ability, affordability, and safety. Currently avail­
able antimalarials do not have optimal 
characteristics in all categories, but choices must 
be made. The following may be useful in the de­
cision process:
For treatment o f  an acute malaria attack: 
This is a serious problem that threatens the life o f 
both mother and fetus; therefore, the character­
istics o f efficacy and availability override safety 
and affordability. Quinine alone for 7 days, qui­
nine treatment for 3 days, followed by sulfa-py- 
rimethamine (SP) combinations, SP alone, 
mefloquine, or halofantrine are likely to be high­
ly effective. Chloroquine (CQ) can be used for 
Plasmodium vivax, P. malariae, and P. ovale infec­
tions where it remains highly effective and in the 
few areas where P. falciparum is fully CQ sensi­
tive.
For treatment or prevention o f  parasitemia 
(asymptomatic): Efficacy, availability, safety, 
and affordability are all im portant characteristics 
to be considered in the decision process. An ini­
tial treatment dose is required to  clear para­
sitemia from the high proportion o f pregnant 
women who will have asymptomatic parasitemia. 
In settings where it remains highly effective, CQ 
can be used for this treatment (25 mg base/kg) 
and then continued as weekly prophylaxis (5 mg 
base/kg, equal to 300 mg base per week). With 
the increasing number o f areas where CQ is no 
longer highly effective, alternatives include SP, 
biguanides (proguanil and chlorproguanil), and 
pyrimethamine. Resistance to pyrimethamine is 
widespread and its efficacy must be proven be­
fore choosing this alternative. The biguanides 
are not recommended as initial treatment and 
must be given daily for prophylaxis. Compliance 
is a problem, and efficacy must be monitored. 
Recent studies with SP suggest that single dose 
therapy at first antenatal clinic and again at the 
beginning o f the third trimester was highly effec­
tive in a highly endemic area in treating and pre­
venting malaria. This regimen would be 
affordable and easily deliverable in conjunction 
with tetanus toxoid administration, which should 
be given at approximately the same times.
Other drugs (e.g., mefloquine, halofantrine) 
are less available and more expensive; and less is 
known about their adverse effects during preg­
nancy.
3 1
M A L A R I A  I N  P R E G N A N C Y
drugs can be used during pregnancy because of pharmacologic characteristics and 
potential adverse effects. With spreading parasite resistance to CQ, the number of 
available alternative effective drugs is an important consideration (Box 2.14).
Before a drug is chosen, logistics issues, including availability and affordability, must 
be examined. If prenatal care is provided through clinic services, all clinics must have 
a ready supply of the drug; if care is provided in communities with local attendants, 
drugs must be made available in the community. Where women must purchase the 
drug themselves, it must be affordable, especially for the poorest women, who may 
need it most.
Finally, investigators have noted that acceptance and compliance by pregnant 
women are critical in establishing an effective program (Heymann et al. 1990). In 
Malawi, where local custom suggests that women avoid bitter food and medicine 
during pregnancy, bitter-tasting CQ, which had been recommended as the antima- 
larial for chemoprophylaxis in pregnancy, was met with poor acceptance and compli­
ance by the women. Interm ittent treatment that could be given at monthly (or less 
frequent) antenatal clinic visits or at 
similar intervals in a community- 
based care system would constitute a 
more effective intervention simply by 
eliminating the need for compliance 
at home with a weekly or daily dos­
ing regimen.
The epidemiology of malaria, the 
parasite's response to antimalarial 
drugs, and the epidemiology of LBW 
affect the prevention program. If  an 
evaluation demonstrates a high prev­
alence o f LBW (>15%) in primigrávi­
das and of malaria infection (>15%) 
in primigrávidas at the time o f enroll­
ment in antenatal clinics, treatment 
with an effective antimalarial drug 
will reduce placental infection and 
lower the incidence o f LBW. Inter­
mittent therapy or regular chemo­
prophylaxis will then be necessary to 
keep the placenta parasite-free.
Although few affordable, safe, and effective drugs are available for use during preg­
nancy, SP has recently been shown to be effective when given as intermittent therapy 
(Box 2.15). The administration of a prevention regimen should be limited to preg­
nant women in their first and second pregnancies if local epidemiologic studies con­
firm that these are the at-risk pregnancies. If malaria transmission is highly seasonal, 
these measures could be applied specifically during the high transmission season 
(beginning with the start o f the increase in transmission and continuing for 2-3 
months after transmission has returned to low levels).
Box 2 .15  Sulfadoxine-pyrimethamine U se D uring  
Pregnancy
In 1992, a study in Malawi investigated the use o f sulfa­
doxine-pyrimethamine (SP) as an effective and practical 
drug in Africa for control o f malaria during pregnancy. Dur­
ing the rainy and postrainy season, women (N=566) in their 
first or second pregnancies who were between 16-32 weeks 
gestation were enrolled and placed on one o f three antima­
larial regimens: chloroquine (CQ) treatment followed by 
CQ weekly prophylaxis; SP treatment followed by CQ 
weekly; SP treatment twice-at first visit and again in early 
third trimester. Outcomes measured were parasitemia and 
placental infection at delivery.
Placental infection was seen in 50% of women on CQ 
alone, 37% of women on SP-CQ, and only 9% o f women on 
SP/SP. Women receiving the two-dose SP regimen had a 
significantly lower prevalence o f placental infection than 
women on either CQ regimen, p<0.05. The two-dose reg­
imen could be coupled with tetanus toxoid administration 
and would provide a simple, affordable, and effective malar­
ia prevention regimen for pregnant women in areas o f CQ- 
resistant P. falciparum.
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Introduction
By increasing malaria morbidity and mortality and adding a layer o f complexity to the 
management of malaria illness, the extension o f CQ-resistant Plasmodium falciparum  
has forced health professionals to broaden malaria control efforts. Older methods 
are being reconsidered; new measures are being sought.
A number o f malaria control measures-environmental, barrier, chemical, and bio- 
logic-have the potential to reduce malaria transmission (Box 2.16). They can either 
reduce the vector population or interrupt the vector-human contact.
Box 2 .1 6  Transmission Prevention
1. Environmental measures can decrease transmission by decreasing vector breeding sites 
through water management (drainage, ditching, filling, or weed removal).
2. Barrier measures impair transmission by limiting physical contact between vector and host. 
These personal protection methods include clothing, bed nets, and curtains. Recently, insecti­
cides have been used to impregnate bed nets and curtains, resulting in a combination o f the bar­
rier and chemical control measures.
3. Chemical measures affect transmission by killing anopheline mosquitoes or their larvae with 
insecticides. Measures include indoor residual spraying with insecticides (e.g., DDT, malathion, 
fenitrothion, and bendiocarb); outdoor application o f larvicides that attack the mosquito larvae 
in their breeding sites (e.g., temophos, methoprene); indoor and outside space spraying 
(malathion); and personal protection measures such as repellents and coils, which use chemicals 
such as DEET, pyrethrins, and pyrethroids.
4. Biologic measures interfere with transmission by increasing the number o f anopheline pred­
ators, which include fish (e.g., top-feeding minnows), nematodes, and aquatic fungi that show 
promise as larvicidal agents, and a toxin o f strains o f the bacteria Bacillus thuringiensis. Many of 
these remain as research tools and have not been widely employed.
Although these various methods may be quite effective when properly applied, they 
are all costly; each has major technical or labor requirements and may be difficult to 
sustain.
• Environmental modification is appropriate where breeding sources are confined 
and easily identified and where a readily available, moderately skilled, labor force 
exists (e.g., in urban areas); thus, this method may be less practical in rural or 
semirural areas.
• Chemical control measures must be carried out within a vertical program and 
require trained staff and a continuous supply of insecticide and spray equipment. 
These measures have limited applicability for a primary health care program. Use 
o f pesticides, like the use of antimalarial drugs, engenders resistance. Detecting 
resistance requires frequent monitoring and, once detected, newer, more expen­
sive insecticides must be substituted.
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• Biologic methods, although intriguing, have not been effective in large-scale field 
settings.
Environmental, chemical, and biologic methods have not been easily initiated or sus­
tainable in African malaria control efforts. The expense involved and the requirement 
for sustained effort combine to compromise their potential efficacy.
However, among the barrier methods, insecticide-impregnated bed nets (IBNs), 
have generated much interest in recent years. Because some studies have suggested 
that IBNs have great potential for individuals and communities, their use is being 
examined in different epidemiologic settings in Africa.
Reducing malaria transmission with insecticide-impregnated bed nets
Bed nets are an age-old technique for decreasing human contact with insects and 
increasing privacy. Recently, bed nets impregnated with an insecticide, commonly 
one of the nontoxic synthetic pyrethroids, have been evaluated for malaria preven­
tion. Impregnation enhances protection by killing the insects on contact or by repel­
ling them from the sleeping area. The anticipated effects of widespread use of IBNs 
are a decline in human-vector contact, a decrease in the density of infective vectors, 
and a reduction in malaria transmission, with a consequent decline in malaria-related 
morbidity and mortality (Greenwood and Baker 1993).
Several studies have indicated that IBNs are effective in reducing inoculation rates, in 
reducing the incidence of malaria disease, and in lowering malaria-related mortality 
(Box 2.17).
Box 2 .1 7  Efficacy o f  Insecticide-impregnated Bed N ets
The Centers for Disease Control and Prevention investigations o f impregnated bed nets (and 
curtains), in collaboration with the Kenya Medical Research Institute, indicated significant decreas­
es after 1 year o f use in the presence o f Anopheles gambiae, in entomologic inoculation rates (EIRs), 
in acquisition o f Plasmodium falciparum infection (malaria incidence), in development o f high par­
asitemia levels (>2,500 parasites/m m 3), and in the frequency o f clinical malaria episodes. Trans­
mission in the study area o f western Kenya is approximately 100-200 infective bites per person per 
year (Beier et al. 1990).
Another widely cited recent study designed to measure the effect o f permethrin-treated nets on 
child mortality was carried out in a population o f over 20,000 in The Gambia, an area o f moderate 
and seasonal transmission (EIR = 5 10) (Alonso et al. 1991). In 1 year among children between 
the ages o f 1 and 4 years, overall mortality and malaria-related mortality were reduced by 63% and 
70%, respectively.
However, although some studies show positive results, investigators generally agree 
that additional data are required to evaluate whether IBNs are effective in reducing 
malaria mortality in malarious areas with perennial heavy transmission. Issues requir­
ing further study are outlined in Box 2.18.
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Target groups
Insecticide-impregnated bed nets can be 
targeted to two different groups:
• Individuals: While little evaluation 
of the effect o f personal use o f IBNs 
has been done, there is consensus 
that IBN use for individuals is advis­
able. If used correctly, bed nets 
reduce the person's chances of being 
bitten by infected mosquitoes. Fami­
lies who can afford to purchase nets 
and keep them properly impregnated 
should be encouraged to do so. In 
the promotion of IBNs, emphasis 
should be placed on the value of pro­
tecting young children and women of 
reproductive age from sundown to 
sunrise.
• Communities: The use of IBNs by a 
high proportion of people in commu­
nities will lead to decreased malaria- 
related morbidity and mortality 
through community-wide reduction 
of transmission.
Mosquitoes that are diverted from biting 
persons sleeping under IBNs may seek 
others not sleeping under IBNs, thus 
increasing exposure to malaria parasites 
for the unprotected. Universal coverage 
is ideal, as the reservoir o f gametocytes 
necessary to maintain malaria transmis­
sion would be greatly decreased. There­
fore, efforts should be made to have as 
many persons as possible in a community 
use IBNs.
Reducing malaria transmission: objective
• To reduce transmission of malaria infection.
Reducing malaria transmission: strategy
• Use IBNs during nighttime sleeping hours in endemic areas.
Factors affecting insecticide-impregnated bed-net use
Using impregnated bed nets on a community-wide basis necessitates overcoming a 
number o f obstacles to implementing the strategy. Behavioral considerations; the
Box 2 .18  Research Issues for Insecticide- 
impregnated Bed N ets
1. Studies need to be carried out in differ­
ent epidemiologic milieus. To date, most 
studies have been carried out in areas o f low 
transmission (entomologie inoculation rates 
[EIRs] in the range o f 0.5-15 infective bites 
per person per year). Since malaria intensity 
and potential vector biting and resting hab­
its differ in low and high transmission set­
tings, evaluation o f bed-net efficacy should 
be carried out in environments with differ­
ent transmission patterns.
2. A standard methodology must be used. 
Many o f the early studies focused on ento­
mologie indices. Standard clinical, behav­
ioral, operational, and economic issues 
should be examined.
3. Decreased sensitivity o f Anopheles mos­
quitoes to permethrin-impregnated nets has 
been observed in Kenya. This finding iden­
tifies the need for insecticide sensitivity sur­
veillance, efficacy studies o f newer and 
alternate insecticidal products, and evalua­
tion o f bed-net material-insecticide-binding 
properties that determine the duration o f 
insecticide effect.
4. The cumulative and long-term effects o f 
insecticide-impregnated bed nets on parasi­
tologic, entomologie, clinical, immunolog­
ic, behavioral, and economic indices need to 
be assessed over several transmission sea­
sons. Estimating trends over time will allow 
an assessment o f the proportional contribu­
tion o f nets to health impact in light o f such 
intervening events as local epidemics of 
nonmalaria illness, unusually heavy rainfall, 
movements o f populations, and promotion 
o f other public health interventions.
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cost and financing o f IBNs; the logistics involved in procuring, distributing, and 
impregnating IBNs; the technical training and management; and health education- 
all present challenges to the successful use of this intervention.
Behavioral considerations. The IBN intervention should be promoted in settings 
where Anopheles bite mostly indoors. The strategy will be more effective when the 
population involved sleeps inside during the hours of mosquito feeding and when the 
population is amenable to the nightly use of IBNs. Deviations from these behavioral 
patterns will favor continued malaria transmission.
Cost and financing. The cost o f IBNs represents a substantial investment. A dura­
ble net costs between USS5-40, and each family, on average, requires two or more 
IBNs to cover adults and children. Each impregnation of the bed net, which is 
required every 4 to 6 months, costs about US$1. Average per capita annual income 
in some sub-Saharan African countries is estimated at US$300-500 per year, so the 
purchase and maintenance of an IBN could represent approximately 1 %-10% of the 
annual household income.
There are also costs at the national level. Before a bed-net program is promoted, a 
vector assessment is advisable to determine if the mosquitoes transmitting malaria in 
that area are indoor-biting. This assessment is not inexpensive. If it is decided that 
IBNs are an appropriate strategy, and the entire population of a country is to sleep 
under IBNs, IBNs will need to be made or procured, purchased by households, 
impregnated, reimpregnated, and maintained properly. If the Ministry of Health 
(M OH) decides to promote IBNs as a public health intervention, a policy and a 
strategy for IBN-use must be established, specifying the required human and mone­
tary resources and the role of the M O H  in coordinating community participation 
and encouraging private enterprise and donor support.
Subsidies by organizations or the government to purchase IBNs or to impregnate 
them have had some success. Various organizations (e.g., UNICEF) have begun to 
provide nets to local health departments through cost recovery schemes. In western 
Kenya, over 200,000 impregnated nets have been purchased at a fixed price and then 
distributed in the community. In Burkina Faso, the national malaria program has 
established "impregnation centers" where persons can come to have their curtains 
and nets soaked for a modest fee. In The Gambia and Burkina Faso, programs to 
impregnate bed nets in all communities are receiving national and international sup­
port.
Insecticide-impregnated bed nets also have the potential to develop into a cottage 
industry with income-generating opportunities for members o f the community. Rela­
tively few data are available on the willingness o f communities to employ bed nets as 
a public health measure and to make, impregnate, install, and maintain them as a 
business.
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Procurement and distribution. Communities must decide whether they will man­
ufacture or import bed nets, how they will be distributed to all households in the 
community, and how impregnation and regular reimpregnation can be accom­
plished.
Training. Nationals must be trained in the science and technology related to bed 
nets, as well as in the skills necessary to manage a bed-net program. A cadre of work­
ers with experience in impregnating and hanging bed nets and with program man­
agement skills will be needed. Training should emphasize skills needed for the 
planning, management, logistics, and managerial monitoring o f a bed-net program; 
entomology should also be included in training, although it is o f lesser importance. 
Epidemiologic surveillance (perhaps in sentinel villages and health units) should be 
set up to allow continuous evaluation of the effort. Technical issues related to bed- 
net use are outlined in Box 2.19.
Health education and marketing. IBN-use must be promoted within the commu­
nity and the message communicated to all households in an area. Although many of 
the villagers in African countries know of bed nets and have seen them in a home or 
marketplace, fewer than 5% use bed nets, virtually none of which are impregnated 
with insecticide. A recent study designed to measure the effectiveness of bed nets in 
areas of high transmission in Kenya found that bed-net coverage increased to 95% 
during the study. Bed nets were provided to village residents at no cost, and assis­
tance was provided in impregnating and hanging them.
Insecticide-impregnated bed nets: the future
Questions remain regarding the efficacy o f IBNs in a variety of malaria transmission 
settings in sub-Saharan Africa. For countries interested in embarking on a local or a 
national program, two major questions must be answered: Will the IBNs be effective 
in the proposed setting? and Can the factors that affect the success o f a program of 
IBN use be addressed satisfactorily?
As ongoing and anticipated research is completed, our understanding of the efficacy 
of IBNs will increase. Although the studies are time-consuming and costly, each 
country contemplating IBNs as an intervention should begin by evaluating local lev­
els o f transmission, i.e., measuring parasite prevalence and EIRs in representative 
transmission areas o f the country. Results from studies evaluating IBNs in other set­
tings with similar EIRs can then be used to predict the likely efficacy o f IBNs in a 
particular environment.
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Box 2 .1 9  Technical Issues for Insecticide- 
impregnated Bed Nets
Bed-net m odels and sizes: Bed nets can be rectangular, conical, or 
wedge-shaped. The rectangular model is recommended because the sleep­
er is less likely to touch it; thus, the mosquito cannot bite the sleeper 
through the net. Although nets can be made to order locally in some coun­
tries, many persons use the nets produced in Thailand because o f their low 
cost.
Bed-net materials: The most common materials for bed nets are ny­
lon, polyester, and cotton, alone or in combination. Polyethylene is also 
used for nets, although it is somewhat flammable and has been found un­
suitable because holes develop readily. Nylon and polyester produce better 
results in killing and repelling mosquitos. Nylon, polyester, and polyeth­
ylene tend to be more durable than cotton. Strength o f the material affects 
protection; nets o f a lower denier (a measurement o f weight o f fabric) tear 
more easily than those made with a heavier, and therefore, stronger fabric.
Mesh size: Mesh (hole) size must not be so small that persons sleeping 
under the bed net become uncomfortable because o f poor air flow and 
consequendy do not use the net. On the other hand, the mesh size must 
not be so large that if the net is not properly impregnated, the mosquito is 
allowed to  pass through. Recommended is a mesh size o f 1.25 mm2.
Insecticides and dosages: The most commonly used insecticides for 
impregnating bed nets are the pyrethroids, two of which are currently in 
use-permethrin and deltamethrin. Others are being tested. The amount 
needed to impregnate a bed net differs according to the insecticide used 
(Schreck and Self 1985).
Im pregnation procedures: One standard approach is the following:
1. Use a clean net.
2. Calculate size o f netting in meters squared.
3. Calculate amount o f water necessary to soak the net to the point of 
saturation. The type o f material used determines how much water will be 
needed (cotton absorbs approximately 3 times as much water as synthetic 
materials).
4. Calculate the total volume o f insecticide needed to impregnate the 
net.
5. Mix the insecticide and water calculated from 3 and 4.
6. Soak the net with the solution, and then gently wring out any excess 
into a treatment container (plastic sack, large plastic wash tub, or vat).
7. Lay the net on a clean flat surface to dry. Drying the net on the us­
er's mattress provides secondary benefits by controlling bed bugs and o th ­
er pest insects.
8. When the net is almost dry, hang it in a shady place to finish drying.
9. Once the net is dry, hang it over the bed, using string to tie the cor­
ners o f the net to the rafters or to  nails. In some cases, nails may have to 
be provided to the homeowner. Make sure the net is low enough so that 
the bottom  border can be securely tucked in around the bottom o f the 
mattress, thereby preventing mosquito entry.
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Introduction
Malaria infection and illness can be prevented with appropriate chemoprophylaxis, 
i.e., the regular administration of antimalarial drugs. Adequate blood levels o f an 
effective drug will either prevent primary infec­
tion of liver cells (causal prophylaxis) or will 
interrupt the erythrocytic cycle (suppressive pro­
phylaxis) once an individual has been infected.
Few safe and effective causal prophylactics are 
available now.
Those at highest risk of developing life-threaten­
ing malaria illness (nonimmune children, travel­
ers, immigrants) will benefit from 
chemoprophylaxis. The other primary target 
group for chemoprophylaxis is pregnant women 
living in malaria-endemic areas, especially those 
in their first and sometimes their second malaria- 
exposed pregnancies. The use of effective 
chemoprophylaxis in pregnancy has been shown 
to decrease the incidence o f LBW infants in a 
population.
Chemoprophylaxis for children
A number of studies have established that 
chemoprophylaxis is effective in decreasing 
malaria morbidity and mortality among children 
(Box 2.20), yet mass chemoprophylaxis is not 
generally recommended as a malaria control 
strategy. One reason is that choice o f drug is 
problematic: the most affordable drugs (CQ, 
proguanil) have limited use because of parasite 
resistance, the most effective drug (mefloquine) 
is currently very expensive, and other potentially 
useful drugs are limited by severe adverse reac­
tions (Stevens-Johnson syndrome for SP, agranu­
locytosis for dapsone) or other restrictions 
(tetracycline is not advised for pregnant women 
and children <8 years o f age because o f the 
adverse staining effect on the fetus' developing teeth and because o f the adverse 
effects on the mother's liver). In addition, there is a risk that the use of widespread 
chemoprophylaxis will favor the development and spread o f drug-resistant parasites. 
Data differ on this point depending on the drug under consideration, its mode of 
action, and the intensity of the selection pressure exerted on the parasite. Finally, the 
economic and logistic demands of establishing and maintaining programs for
Box 2 .2 0  Experiments in Mass 
Chemoprophylaxis
Greenwood and colleagues 
(1988) have demonstrated re­
ductions in overall mortality, ma- 
laria-specific mortality, and 
number o f episodes o f fever asso­
ciated with malaria parasitemia 
among children after initiation o f 
chemoprophylaxis and treat­
ment. In a réévaluation occurring 
3 to 4 years after initiation o f 
chemoprophylaxis in this area, 
children aged 3-59 months who 
had received chemoprophylaxis 
and treatment experienced a 49% 
reduction in mortality and a 73% 
reduction in clinical attacks of 
malaria compared with a ran­
domly assigned placebo group 
(Menon et al. 1990). Studies 
conducted in Nigeria (Bradley- 
Moore et al. 1985) demonstrated 
improved hematologic status o f 
persons in communities that re­
ceived chemoprophylaxis with 
chloroquine; additional studies 
have demonstrated improved he­
moglobin among those who re­
ceived chemoprophylaxis with 
chloroquine. O ther studies of 
chemoprophylaxis have dem on­
strated similar reductions in m or­
bidity but have been too small to 
detect significant reductions in 
mortality.
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mass chemoprophylaxis are daunting (W HO 1992), and compliance on a popula- 
tion-wide basis has not been high (McCormack and Lwihula 1986).
Targeted chemotherapy. Certain subsets o f children (those with sickle cell anemia, 
immune suppression, and a history o f severe anemia or febrile convulsions) might 
benefit from chemoprophylaxis but supporting data do not exist. Are some children 
at higher risk for complicated malaria than others? Recently it has been shown that 
defined immune responses, such as tum or necrosis factor, mediate the pathology 
associated with severe malaria (Hill et al. 1991), but other risk factors have not been 
determined. If and when they are, it may be feasible to target chemoprophylaxis 
toward children who are known to be at increased risk of developing complicated 
malaria.
In an urban area of seasonal transmission in Malawi, the risks o f developing severe 
anemia or cerebral malaria are highest during the rainy season (January-April). Chil­
dren under the age of 4 years are at highest risk for these complications. The efficacy 
of chemoprophylaxis targeted toward this age group (or, more specifically toward 
children who are known to have had severe anemia or cerebral malaria) and adminis­
tered only during the months o f highest risk has not been studied but may well be a 
cost-effective approach to lowering malaria morbidity and mortality.
At present, because o f the expense involved in sustaining a program, mass chemopro­
phylaxis for children living in endemic areas is generally not advised.
Chemoprophylaxis for travelers and immigrants
Nonimmunes traveling into malarious areas for short periods benefit from malaria 
chemoprophylaxis. Optimal chemoprophylactic regimens will vary from area to area, 
depending on local drug sensitivities. The Centers for Disease Control and Preven­
tion and W HO annually compile recommendations for short-term chemoprophy­
laxis; these booklets provide information for all malaria-endemic areas and should 
be consulted for the development o f individual regimens (CDC 1993).
Chemoprophylaxis for pregnant women
Chemoprophylaxis during pregnancy has been shown to decrease the incidence of 
LBW infants (Steketee et al. 1993). In the appropriate settings, a malaria-specific 
intervention can lower infant mortality rates. For further details, see pages 29-32.
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I n t r o d u c t i o n
The three facets of malaria infection and disease in Africa have been examined and 
strategies recommended for their management and prevention. To control malaria, 
a malaria control program must incorporate interventions appropriate to the epide­
miologic setting and implement them within the infrastructure in health facilities and 
in communities.
T h e  I n f r a s t r u c t u r e  f o r  t h e  M a l a r i a  C o n t r o l  P r o g r a m
The malaria control program should, to the greatest extent possible, use the existing 
health infrastructure to provide quality services. To maximize the efficiency of health 
care delivery, the malaria control program should take advantage of the commonali­
ties malaria control and prevention share with other disease interventions. O ther dis­
ease control programs, such as those for diarrhea and respiratory illness, also 
formulate case management and prevention protocols and treatment recommenda­
tions for acute and chronic cases. O ther interventions also require support activities, 
such as training health care workers in field operations. As malaria control programs 
are developed and expanded in Africa, they must capitalize on similar implementa­
tion activities.
Examples:
• The incorporation o f malaria case management with management of other dis­
eases, e.g., acute respiratory infections and diarrheal diseases, into one case man­
agement algorithm for the "sick child" may ensure that the "febrile" child is 
correctly diagnosed, treated, and referred, if needed. Integration may also 
strengthen each disease control program by avoiding duplicated training courses 
and by sharing commodity procurement processes.
• Malaria prevention for pregnant women should be merged with programs that 
ensure a pregnant woman delivers a healthy baby. These antenatal programs 
include tetanus immunization, syphilis testing and prevention, and pregnancy risk 
assessment and risk management.
• Where a community has decided to use IBNs, the distribution and maintenance 
of nets will require community-based initiatives similar to those required to sup­
port water and sanitation programs.
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R e q u i r e m e n t s  f o r  t h e  M a l a r i a  C o n t r o l  P r o g r a m
A malaria control program requires the following:
• Committed leadership
• A written policy
• A detailed plan for policy execution, often referred to as a "program plan"
• Successful implementation o f the program plan
• A mechanism for monitoring program implementation and evaluating program 
effectiveness
Leadership
Commitment must come from the leaders in the M O H -as witnessed by a written 
policy and by sufficient allocation of funds. A person or a clearly defined unit within 
the government must be given the responsibility and authority to plan and evaluate a 
malaria control program. If the responsibility becomes diffused or if the program 
lacks the necessary authority or resources to implement its plan, the malaria policy 
and plan are less likely to be implemented effectively.
Because the malaria control program may not be a distinct unit within the country's 
public health system, a malaria technical group is required. The leadership and tech­
nical expertise that can be provided by this group are essential for policy formulation 
and program evaluation.
Policy
A malaria control policy provides guidelines to health care workers, program plan­
ners, and donor agencies on disease management and prevention.
The policy consists o f a preamble 
(background information on the pro­
gram), a brief analysis of the current sit­
uation, including epidemiologic 
information, and technical guidelines 
(Box 3.1). The technical guidelines 
state the goal o f the program, identify 
the appropriate interventions (case 
management and prevention), and for 
each intervention, describe what health workers need to be able to do. For case man­
agement, guidelines should specify correct diagnosis, treatment, education and fol- 
low-up, and referral. For prevention interventions, guidelines should specify personal 
protection, chemoprophylaxis, and vector control methods. See Box 3.2 for aspects 
to consider when formulating technical guidelines for case management of malaria.
Policies are most useful when they are written as a brief statement (4-8 page) that is 
approved by government officials, and, for added advantage, by a high level technical
Box 3.1 Malaria Policy Contents
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Box 3 .2  Technical G uideline Considerations
Diagnosis
Acute: The diagnostic tools (such as microscopy and the capability to measure hemoglobin concentration) 
available at peripheral health centers depend on the specific needs o f that center (e.g., the number o f patients 
seen with malaria) and its capacity to  use the tools (e.g., the number o f trained technicians). Referral centers 
should have the full range o f diagnostic equipment, from thermometers to microscopes (W H O /A FR O  1992). 
Chronic: Because managing severe anemia requires documenting the clearance o f parasitemia in addition to 
monitoring the level o f hematologic improvement, health facilities should have the capacity to perform hem o­
globin or hematocrit and microscopic examination o f blood smears. However, since peripheral clinics will 
probably not be able to have such tests available, improving clinical recognition o f anemia is critical.
Perinatal: Health workers in antenatal clinics should be prepared to treat or provide chemoprophylaxis to 
pregnant women coming to the clinic. All pregnant women with malaria illness should be treated, and, de­
pending on the local epidemiology o f malaria, women in their first or second pregnancies need chemoprophy­
laxis.
Treatment
Acute: Because determination o f an appropriate drug dose for an individual child depends on the child's age 
and weight, the health facility will need scales and charts that specify treatment according to age and weight. 
Drugs recommended in the national policy guidelines must be available. Additional supplies for treating severe 
malaria (IV fluids and administration sets) must also be available in facilities where parenteral therapy is given 
(W H O /A FRO  1992).
Chronic: Several malaria drugs must be available in health facilities: where there is resistance to the primary 
drug for malaria (e.g., CQ), a second drug(s) must also be available at the peripheral level so that children at 
greatest risk for the deleterious effects o f chronic parasitemia can be treated to eliminate parasitemia. Once 
life-threatening anemia is detected, health care facilities must have either the capability o f providing blood 
transfusions or have access to immediate referral for the patient. Capabilities include facilities for banking 
blood, performing typing and cross-matching, testing for HIV  (and hepatitis B and C), having supplies (e.g., 
blood bags, administration sets) for blood administration, and having clinical proficiency for supportive care 
(e.g., fluid management).
Perinatal: Antimalarial drugs should be given under observation at the clinic to minimize the problems o f low 
compliance that come with home administration. So that the complete treatment is given, antenatal cards 
should have a space for recording the treatment or prophylaxis provided (including drug dosage and timing).
Patient education and follow -up
Acute: Caretakers must be told the importance o f the febrile child’s completing the drug treatment schedule 
and returning if the fever is not cleared.
Chronic: As additional information is gained on the chronic complications o f malaria, health facility activities 
may need to  be modified.
Perinatal: Pregnant women must understand the importance o f visiting the antenatal clinic once a m onth dur­
ing pregnancy to  receive antenatal care. The delivery o f the malaria intervention should be coupled with other 
activities. For example, antenatal care should include provision o f nutritional supplements and guidance and 
treatment with iron and folate tablets; and interm ittent therapy with sulfa-pyrimethamine could be given in 
conjunction with tetanus toxoid administrations, which require a similar schedule during a woman's first or 
second pregnancy.
Referral
Acute: Appropriate management o f malaria requires referral o f patients with complicated illness and o f patients 
who fail to respond to initial therapy and therefore need further diagnostic evaluation. Referral centers must 
be able to provide the additional diagnostic capability and the necessary treatment. I f  referral is not possible, 
malaria management at peripheral facilities must have guidelines and supplies in order to manage complicated 
cases. A policy o f referring complicated malaria cases has the potential o f centralizing life-saving medical care; 
the care would then be unavailable to the majority o f those with life-threatening illnesses because o f economic 
and logistic constraints.
Chronic: In the case o f life-threatening anemia, facilities must have access to immediate referral for the patient.
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advisory group. The policy must be disseminated to all levels of the government and 
private sector involved in its execution. The statement must be clear and comprehen­
sive so that health workers and government officials can understand the goal of 
malaria control, the recommended interventions, and the strategies. The policy 
statement should be viewed as a dynamic document, to be revised as necessary on the 
basis of experience in implementing the national program.
Program plan
A written program plan states measurable 
impact, outcome, and process objectives that 
are related to one another and to the national 
malaria control policy (Bryce et al. 1993) (Box 
3.3).
• Impact objectives correspond to the prior­
ity goal o f the program (e.g., mortality 
reduction) as stated in the national policy.
Time frame: 5-10 years.
Example: By 2003, malaria-related morbidity in children under 5 years of age 
will be reduced by 25%.
• Outcome objectives correspond to the priority intervention (e.g., case manage­
ment or prevention), priority target population (e.g., children under 5 years of 
age), and those charged with the care o f the target population (health care work­
ers, mothers, family members, etc.). Timeframe: 2-5 years.
Example: By 1998, 90% o f children less than 5 years of age diagnosed with 
malaria in a health facility will receive the correct antimalarial treatment according 
to the national policy guidelines.
• Process objectives correspond to the various activities (training, supervision, 
commodity supply, surveillance, health education, operational research, etc.) nec­
essary to achieve the intended outcomes and impact. Time frame: 1-2 years.
Example: By 1995, 80% o f health workers in a given district will be trained (or 
retrained) in case management protocols for malaria.
The implementation plan lists support activities and tasks to be conducted and speci­
fies who will conduct them and when, where, and how they will be conducted. Sup­
port activities include health worker training, health worker supervision, 
establishment of diagnostic capabilities appropriate to the health facility level, pro­
curement and distribution of antimalarial drugs and supplies, patient education, com­
munity education, and disease surveillance. These activities are needed to ensure that 
the patient receives the needed attention at the health care facility and that patients 
will continue appropriate care in the home. Only if the health worker is properly sup­
ported can a malaria program provide adequate case management of patients.
Box 3 .3  Malaria Program Plan 
Contents
• Impact, outcome, and process
objectives and indicators
• Implementation plan for support
activities
• Monitoring and evaluation plan
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These support activities need to be prioritized. Resources, both human and financial, 
will probably be limited; clearly stating which activities have the highest priority is 
important so that existing resources will be used effectively.
Monitoring and evaluation plans need to be included. Monitoring plans describe 
how to monitor activities and tasks, who will perform the monitoring, what methods 
will be used, and how often monitoring will be conducted. Evaluation plans describe 
how to measure attainment o f outcome and impact objectives, who is responsible for 
evaluations, what methods and data sources will be used, how often data will be col­
lected, and to whom it will be reported. The plan should also specify how monitor­
ing and evaluation results will be used to improve program activities and achieve 
objectives.
A program plan should include a detailed time line and budget for conducting activi­
ties. It may also describe the organizational structure of the malaria control pro­
gram.
Program implementation
To achieve the objectives, the program plan needs to be implemented fully. There­
fore, the Malaria Control Program needs to maintain a technically capable staff that 
can develop and carry out the plan.
Program monitoring can assess whether the program plan is being implemented as 
designed-that health worker training is occurring as planned, supervision is being 
conducted, the necessary commodities are available in the facilities specified in the 
implementation plan, needed data are being collected by the health information sys­
tem, and health education materials are being disseminated to the appropriate 
groups. If these activities are not being conducted as specified, leadership should 
determine why the activities are not being carried out and institute remedial actions 
to ensure that activities do occur as originally planned.
M onitoring, evaluation, and operational research
To ensure the effectiveness o f specific interventions and o f the overall program, a 
Malaria Control Program must have monitoring, evaluation, and operational 
research systems, which are outlined in the program plan. Monitoring is the ongoing 
process of tracking program implementation, generally through process measures. 
Evaluation is the periodic measurement of indicators that show the success in attain­
ing program objectives. Operational research is the use of periodic, focused research 
to improve program implementation.
The monitoring and evaluation system must be based either on indicators (i.e., mea­
surements that can be repeated over time to track progress toward the achievement 
of objectives) or on a set o f criteria, or technical standards. Criteria or technical stan­
dards, unlike indicators, may not be quantifiable variables. Criteria used to judge a 
program policy, for example, might include whether the policy is realistic given cur­
rent resources or whether it reflects the national epidemiologic situation.
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The goal of most malaria programs is to reduce malaria-related mortality, and this 
should be reflected in the impact objectives. Evaluation of mortality reduction is 
difficult for two reasons: most o f the mortality due to malaria occurs not in the 
health facilities, where it can be reported, but in the community; and the opportuni­
ties for microscopic confirmation of malaria are limited. Therefore, with only frag­
mentary impact measurements for routine evaluation possible, more emphasis should 
be placed on assessing intermediate outcomes o f program activities that have a 
proven relationship to morbidity and mortality (e.g., proportion of patients diag­
nosed as having malaria by the provider who are prescribed treatment in accordance 
with national policy).
To evaluate the success of an outcome objective (corresponding to a particular inter­
vention), the malaria control staff must gather information about the key elements of 
malaria control activities. The country's Health Information System (if adequate), 
facility-based assessments, community-based surveys, or special operational research 
studies may be used as needed to supply essential information.
Program support activities, such as training, specified in the process objectives should 
be monitored periodically to determine if these activities are being implemented as 
planned.
Operational research is required to solve problems that are identified through moni­
toring or evaluation activities and to provide data to improve policies for malaria con­
trol. The malaria control program needs the technical and financial resources and 
flexibility to carry out defined, time-limited research studies to improve the program. 
This type o f research is different from ongoing monitoring and periodic evaluation in 
that the operational research is aimed at providing a specific answer to a specific ques­
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Malaria vaccine research has to date concentrated on P. falciparum  because it is the 
most important species in causing most of malaria-related mortality and because it is 
the only species that can be cultivated (Institute o f Medicine 1991). The potential 
targets in the parasite life cycle for the development o f vaccines have been the sporo- 
zoite and the developing schizont in the liver (preerythrocytic), the asexual parasites 
in the red blood cell (erythrocytic), and the gametocyte and reproductive cycle in the 
mosquito.
Immunity to the surface protein o f the irradiated P. falciparum  sporozoites can be 
induced in humans; this immunity impairs the infectivity of the sporozoite and its 
development in the liver cell. Providing irradiated sporozoites as vaccines is too 
expensive to be practical; development of subunit vaccines as effective as the irradi­
ated sporozoites has not been possible.
The erythrocytic stages of the P. falciparum  parasite are more complex than sporozo­
ites. A vast array o f potential antigens has been identified, many of which may have 
vaccine potential. Several important features of the parasite biology have emerged 
that complicate vaccine development against the pre-erythrocytic stages. The geo­
graphic variation in the structure o f many of the proteins suggests that a single-anti- 
gen vaccine would have to incorporate multiple versions o f that antigen. An even 
more profound complication is that major parasite antigens exist in various versions 
(alleles) and can mutate; this can occur in a discrete, small geographic area. Genetic 
polymorphism, as well as the capacity to undergo mutation, may have evolved as 
avoidance mechanisms for the parasite. Recognition of these possibilities must be 
incorporated in malaria vaccine development strategies.
Vaccines targeted against the sexual stages of the P. falciparum  life cycle would not 
have a direct effect on the infection or disease in the individual. Such vaccines would 
decrease transmission by impairing the ability o f gametocytes to replicate in the mos­
quito gut. A transmission-blocking vaccine could lead to decreased risk of infection 
for the entire population. Just as community-wide participation is important when 
bed nets are used to decrease transmission, a high proportion of the population 
would need immunization with a transmission-blocking vaccine before an effect 
would be noticeable. During the past decade, several very promising vaccine candi­
date antigens have been identified both on the falciparum gametocyte and the devel­
oping parasite in the mosquito.
T h e  p r o m i s e  o f  v a c c i n e s  f o r  m a l a r i a  c o n t r o l  i n  A f r i c a
Eventually a series of malaria vaccines will be developed that will provide an array of 
protective immunity against malaria infection and disease. A great deal o f basic 
research is required to unravel the mechanisms of naturally occurring immunity and 
to formulate effective vaccines. The time and resources required for the clinical test­
ing of candidate vaccines alone make it seem unlikely that malaria vaccines will be 
available for use in Africa during the current decade. Investing in the study of 
malaria immunity must remain a priority, however, because immunity is the key fac­
tor determining the precarious balance between the human host and the falciparum
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parasite. Current malaria control strategies must recognize the essential role o f natu­
ral immunity in limiting the severity of malaria infection. In the future, control pro­
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